[
    {
        "pmid": "40816710",
        "title": "Commercialization of cell and gene therapy in Canada: Current landscape, challenges and opportunities.",
        "abstract": "Cell gene therapy CGTs offer transformative treatment certain genetic disease cancers growing number global approvals Yet Canadian commercialization lag behind USA Europe review identifies key barrier proposes policy solution informed international examples policyoriented environmental scan conducted using regulatory documents peerreviewed literature government reports industry publications Barriers solution organized four domains regulation manufacturing pricing reimbursement access equity Despite recent investment downturn therapeutic area Canadas approval first clustered regularly interspaced short palindromic repeat CRISPRbased therapy chimeric antigen receptor CAR Tcell expansion suggest future growth Strategic reform could improve domestic CGT innovation affordability equitable access",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40816710/",
        "source_type": "Global"
    },
    {
        "pmid": "40815523",
        "title": "Prices and Affordability of Essential Medicines in 72 Low-, Middle-, and High-Income Markets.",
        "abstract": "Little known price affordability medicine included World Health Organizations Model List Essential Medicines vary across globe compare list price affordability essential medicine across high middle lowincome markets crosssectional study examined data 2022 list price volume 549 essential medicine 72 high middle lowincome market covering 87 countries data obtained IQVIA statistical analysis performed August 2024 March 2025 Laspeyres price index used compare average drug price across countries nominal purchasing power parityadjusted terms affordability 8 essential medicines used treat major cause death disability globally assessed calculating many day minimum wage would required pay 1 month treatment availability essential medicine ranged 225 41 Kuwait 438 80 Germany base country accounting purchasing power parities price essential medicine Lebanon were average 181 Germany Lebanon price index 181 v Germany price index 100 average price US 30 time higher Germany US price index 2982 positive association observed countries gross domestic product per caput expressed logarithmic terms nominal drug price R  030 P  01 indicating richer country generally higher drug prices However adjusting purchasing power different currencies inverse association observed R  035 P  003 suggesting richer country lower real prices Drug affordability measured number days minimum wage needed purchase months treatment varied widely median affordability highest Europe Western Pacific lowest Africa Southeast Asia result crosssectional analysis showed significant variation price affordability 549 essential medicine across 72 market 2022 Strategies promote equitable drug price improve drug affordability urgently needed",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40815523/",
        "source_type": "Global"
    },
    {
        "pmid": "40813984",
        "title": "The impact of deep brain stimulation payment adjustments on healthcare utilization in Shanghai, China: a regression discontinuity analysis of health insurance claims.",
        "abstract": "Recently financial burden medical insurance fund increased rapidly policy effect paying innovation await scientific measurement study us DBS highvalue medical product example quantify causal effect insurance coverage change healthcare utilization informing global valuebased payment strategies identified 2665 DBSrelated records excluding case missing data implantation diagnosis comorbidity management device adjustment presurgery admissions abnormal length stay 2471 case included analysis nonparametric sharp regression discontinuity design adopted assess causal effect reimbursement strategy adjustment eight measure healthcare utilization addition performed robustness analyses reimbursement strategy adjustment significantly reduced individual outofpocket expenditure β10905130 P  0001 increased medical insurance reimbursement cost β  12834714 P  0001 shortened average length recovery β2823 P  001and average length stay β3741 P  0001 accounting covariates result remained significant though effect estimate attenuated suggesting strong association demographic medical characteristic healthcare utilization Additionally effect total surgical cost surgical consumable cost proportion drug cost statistically significant 005 level medical insurance reimbursement strategy adjustment effectively reduces patients economic burden improves healthcare utilization However crucial consider strengthening cost monitoring highvalue medical technologies optimizing clinical pathways balancing interest patients hospitals insurance funds",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40813984/",
        "source_type": "Global"
    },
    {
        "pmid": "40811746",
        "title": "Pharmaceutical expenditure changes under the volume-based procurement policy: Effects and influencing factors.",
        "abstract": "estimate impact Chinas volumebased procurement VBP policy expenditure policycovered uncovered drugs identify element contribute drug expenditure change VBP policy Using national drug procurement data public medical institutions study included 25 policycovered VBP drug 99 policyuncovered alternative drug samples seven 47 pilot city eight 47 expansion province observation regions Timevarying differenceindifference DID model applied quantify policy impact drug expenditures drug expenditure index decomposition method employed analyze determinant drug expenditure change following VBP policy expenditure VBP drug significantly decreased 4219 VBP policy β  055 p  0001 alternative drug increased 1152 β  011 p  0001 significant reduction overall expenditure observed drug β  005 p  0001 decrease VBP drug expenditure showed trend tertiary hospital β  064 p  0001  secondary hospital β  057 p  0001  primary healthcare center β  039 p  0001 index decomposition showed manufacturer structure index IM decline primary driver expenditure reduction policycovered drugs IM decrease 5417 pilot city 4086 expansion regions secondary driver price index IP decline 3168 pilot city 3608 expansion regions restraining factor quantity index IQ increasing 9254 pilot city 5204 expansion regions IQ also drove increase alternative drug expenditures increasing 9556 pilot city 3276 expansion regions VBP policy effectively promoted decline total drug expenditures primarily manufacturerlevel market displacement absolute price reduction However spillover effect alternative drug weakened overall effect cost control Strengthening holistic governance improving quality intensiveness drug use important direction future policy perfection",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40811746/",
        "source_type": "Global"
    },
    {
        "pmid": "40791629",
        "title": "Global burden on drug use disorders from 1990 to 2021 and projections to 2046.",
        "abstract": "Drug use disorder DUDs continue pose heavy burden individuals families societies Despite extensive research remains paucity comprehensive report spatiotemporal distribution driving factors future trend DUDs global regional national levels study aim address gap investigating critical aspect DUDs epidemic Annual data DUDsrelated burden collected Global Burden Diseases injuries risk factor Study GBD 2021 Ageperiodcohort APC analysis estimated annual percentage change used evaluate spatiotemporal trend burden Decomposition analysis used identify temporal populationspecific variation burden slope index inequality concentration index utilized summarize health inequality burden Frontier analysis performed evaluate relationship burden DUDs sociodemographic development Nordpred model Bayesian ageperiodcohort BAPC model introduced forecast burden 2021 global prevalence DUDs reached 53115936 95 UI 4699980560949054 marking 3550 increase since 1990 projected continue rising next 25 years increment incidence deaths disabilityadjusted life year DALYs 3550 12222 7465 respectively Despite declining trend global rate incidence prevalence DALYs mortality still show upward trend increasing 126 165 per 100000 Opioid cocaine use disorder primary contributor overall increase DUDs DALYs 8207 5957 respectively Population growth primary driver increase DUDs DALYs 3531 higher burden observed male population aged 1539 years Health inequality insufficient healthcare performance regarding DUDs remain prominent issue high low sociodemographic index SDI regions study underscore persistent evolving nature DUDs Future research focus understanding complex interplay age gender disparities socioeconomic development drug policies DUDs burden inform effective global strategies",
        "mesh_terms": [
            "Humans",
            "Male",
            "Female",
            "Substance-Related Disorders",
            "Adult",
            "Global Health",
            "Middle Aged",
            "Global Burden of Disease",
            "Adolescent",
            "Prevalence",
            "Young Adult",
            "Cost of Illness",
            "Risk Factors",
            "Forecasting",
            "Quality-Adjusted Life Years"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40791629/",
        "source_type": "Global"
    },
    {
        "pmid": "40789697",
        "title": "Trends in 25 years of antihypertensive agent utilization in Croatia - an alert for scientific community and healthcare providers.",
        "abstract": "Hypertension leading modifiable risk factor cardiovascular mortality worldwide study aimed evaluate 25year trend antihypertensive agent AHA utilization Croatia 2000 2024 conducted national populationbased analysis using IMS IQVIA pharmaceutical databases Drug utilization measured defined daily dos per 1000 inhabitant per day DDD1000day alongside trend financial expenditure prescribing patterns 2000 2024 total AHA utilization tripled increasing 14457 43913 DDD1000day Agents acting reninangiotensin system RAS prescribed class throughout period prescribing volume rising 335 largely driven increased utilization fixeddose combinations Class shift included growing uptake βblockers RAS inhibitors alongside relative decline calcium channel blocker diuretics Total national expenditure AHAs increased €5362 million 2000 €9661 million 2024 reflecting evolving market dynamic sustained decrease average drug price per DDD change related broader access AHAs expanding role combination therapy regimen completely parallel introduction updated international guidelines Nevertheless demographic pressures clinical inertia policyrelated barrier continue constrain optimal blood pressure control finding highlight importance aligning national prescribing practice clinical evidence health system reform improve longterm cardiokidneymetabolic outcomes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40789697/",
        "source_type": "Global"
    },
    {
        "pmid": "40789184",
        "title": "Bolstering the Medication Supply Chain and Ameliorating Medication Shortages: A Position Paper From the American College of Physicians.",
        "abstract": "US health care system experiencing numerous supply chain disruptions including important medications Prescription drug shortage record level affected drug recent years especially generic sterile injectables lowmargin medications shortage arise confluence factors including complexity entire production delivery supply chain quality issues outdated manufacturing facility practices drug purchasing policy prioritize lowest price reliable production change prescribing usage patterns geopolitical constraints market concentration among factors prescription drug shortage patient face negative health outcome due unable obtain necessary treatments stress associated securing medications adverse effect alternative treatments Physicians also face substantial burden navigating drug shortage must expend time resource identifying alternative treatment option obtaining prior authorization coverage alternative drugs negatively affecting patientphysician relationship Policymakers regulators manufacturers health systems health professionals relevant entity must collaborate effort ameliorate drug shortage promote equitable access treatments addition shortterm measure address immediate effect drug shortages policymakers manufacturers drug purchaser also undertake effort prevent future drug shortage investing in strengthening diversifying prescription drug supply chain incentivizing procurement practice emphasize reliable sustainable production practices effort must undergirded policy improve monitoring transparency prescription drug supply chain",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40789184/",
        "source_type": "Global"
    },
    {
        "pmid": "40779264",
        "title": "Changes in Cardiovascular Risk Factors and Health Care Expenditures Among Patients Prescribed Semaglutide.",
        "abstract": "Semaglutide glucagonlike peptide1 receptor agonist demonstrated substantial weight reduction cardiovascular benefit clinical trials However association clinical outcome health care expenditure remains underexplored evaluate change cardiovascular risk factor health care expenditure among patient prescribed semaglutide across multicenter cohorts retrospective cohort study included 23 522 adult ≥18 years received initial semaglutide prescription January 1 2018 January 1 2025 Sentara Healthcare January 1 2018 May 1 2025 Yale New Health System first prescription semaglutide identified ingredient level stratified type 2 diabetes status Primary outcome included change weight  baseline blood pressure BP total cholesterol hemoglobin A1c Secondary outcome assessed health care expenditure using Medicarebased cost estimates staggered differenceindifferences design compared outcome patient first semaglutide prescription patient yet received prescription period study cohort included 23 522 patient mean SD age initiation semaglutide 562 129 years 667 female 686 diabetes overall cohort initiation semaglutide significantly associated 38 95 CI 39 37 reduction weight 13 24 months 51 95 CI 55 47 reduction weight among patient without diabetes Significant reduction diastolic BP 15 mm Hg 95 CI 17 14 mm Hg systolic BP 11 mm Hg 95 CI 14 08 mm Hg total cholesterol 128 mgdL 95 CI 143 114 mgdL also observed Hemoglobin A1c reduction greater among patient diabetes 03 95 CI 03 02 compared patient without diabetes 01 95 CI 02 001 Imputed health care expenditures excluding cost semaglutide increased 80 per month 95 CI 6892 per month 13 24month period associated inpatient stay shifting expensive circulatory metabolic diagnoses cohort study adult prescribed semaglutide initiation associated reduction weight cardiovascular risk factor increase health care expenditures excluding semaglutide costs finding suggest potential clinical benefit routine practice highlighting need evaluate longterm impact semaglutide economic outcomes",
        "mesh_terms": [
            "Adult",
            "Aged",
            "Female",
            "Humans",
            "Male",
            "Middle Aged",
            "Blood Pressure",
            "Cardiovascular Diseases",
            "Diabetes Mellitus, Type 2",
            "Glycated Hemoglobin",
            "Health Expenditures",
            "Heart Disease Risk Factors",
            "Retrospective Studies",
            "United States",
            "Glucagon-Like Peptide-1 Receptor Agonists",
            "Glucagon-Like Peptide 1"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40779264/",
        "source_type": "Global"
    },
    {
        "pmid": "40779257",
        "title": "Prescription Drug Utilization and Spending by Race, Ethnicity, Payer, Health Condition, and US State.",
        "abstract": "Achieving equitable access medicine requires understanding pharmaceutical use spending vary race ethnicity across US quantify variation prescription drug utilization spending per caput per prevalent case race ethnicity health condition payer US state crosssectional study US Disease Expenditure project extended incorporate disaggregation race ethnicity statelevel retail prescription drug utilization spendingin addition 143 health conditions 38 age sex groups 4 payer Medicare Medicaid private insurance pocketacross 2019 population 50 state Washington DC Data analyzed October 2023 April 2025 Four mutually exclusive racial ethnic group Asian Pacific Islander Black Hispanic White Outcomes include prescription dispensed spending retail pharmaceuticals Estimates standardized population size population age andwhere data permittedby disease burden 52 conditions Das Gupta decomposition used estimate relative contribution 3 factor disease prevalence prescription per prevalent case spending per prescription observed disparity agestandardized per caput pharmaceutical spending 2019 agestandardized pharmaceutical utilization spending per person given disease substantially lower allpopulation mean Black populations close mean Hispanic populations often higher mean Asian Pacific Islander White populations trendsparticularly Black populationwere generally consistent across 52 health condition varied widely across payer US states decomposition analysis 52 condition showed difference per caput pharmaceutical spending across race ethnicity group primarily explained disease prevalence Black population associated increased per caput spending utilization rate per prevalent case Hispanic population also associated increased spending contrast difference drug price product type spending per prescription contributed less observed spending disparities crosssectional study racial ethnic disparity medication use persisted notably underutilization medicine relative disease burden among Black populations pattern varied state highlighting need local conditionspecific approach advancing pharmacoequity US",
        "mesh_terms": [
            "Humans",
            "United States",
            "Cross-Sectional Studies",
            "Ethnicity",
            "Health Expenditures",
            "Prescription Drugs",
            "Racial Groups",
            "Male",
            "Female",
            "Drug Utilization",
            "Middle Aged",
            "Adult",
            "Aged"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40779257/",
        "source_type": "Global"
    },
    {
        "pmid": "40779237",
        "title": "A Framework for Considering the Role of the Public Sector in R&D of Health Technology.",
        "abstract": "development health technology involves complex costly risky investments significant contribution public private sectors Recent EU pharmaceutical directive propose transparency public funding aid pricing negotiation affordability However question remain regarding public investment measured influence pricing reimbursement PR decisions paper characterise public sector institution payers RD investors regulators myriad agency decisions institution directly indirectly sometime unexpectedly influence risk return private research development RD PR direct investments regulatory policy PR decision payer innovative therapy influence risk expected return future RD Valuebased pricing offer reliable signal payers priority costplus international reference pricing greatest impact public RD investment directed area market deficient basic science translational research realworld studies towards emerging field like AI gene editing play increasing role healthcare drug development Applied RD conducted financially sustainable basis Licensing arrangement used recover investments promoting spillover benefit wider society Market access regulator aware need scrupulous transparency neutrality public sector actor payers RD investors also must recognise policy affect level playing field",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40779237/",
        "source_type": "Global"
    },
    {
        "pmid": "40775352",
        "title": "Multiple first-line therapeutic strategies to mitigate artemisinin resistance: cost analysis of a pilot study from a health system perspective in Kaya health district, Burkina Faso.",
        "abstract": "emergence artemisinin resistance Africa increasingly evident threat malaria control elimination anticipatory measure needed Mathematical modelling study demonstrated simultaneous deployment multiple firstline therapy MFT strategy delay spread resistance evidence concerning implementation strategies important factor decisionmaking Incremental financial cost implementing MFT strategy district scale estimated analysed compared routine practice scalingup perspective government Then implication finding improving malaria control Burkina Faso part subSaharan Africa highlighted Microcosting activitybased costing approach used assess cost providers MFT pilot study implemented Kaya Heath District December 2019 November 2020 Quantitative et qualitative data collected seven semistructured thirtyeight structured interviews interview conducted research team including member National Malaria Control Programme health district official chief doctor chief pharmacist manager public health facility MFT strategy implemented six activity involved routine malaria care delivery four incur additional cost MFT strategy implemented support material production health worker training supervision chosen artemisininbased combination therapy ACT costs different standard cost basis uncomplicated malaria case reported national level 2022 MFT implementation cost country level estimated 20840880 USD 92 related drug cost recurrent character weight drug cost MFT strategy depends artemisininbased combination chosen subsidy free care policies pilot strategy cost MFT drug double routine practice 19175568 USD versus 8554365 USD result MFT strategy cost analysis presented may assist policy maker choice malaria ACT combination mitigating emergence drug resistance Although MFT strategy cost almost twice much current single firstline treatment strategy cost saving due avoiding treatment failure likely substantial result also highlight necessity better organizing stabilizing malaria control financing source particularly view recent funding challenge facing global health system",
        "mesh_terms": [
            "Burkina Faso",
            "Pilot Projects",
            "Artemisinins",
            "Antimalarials",
            "Drug Resistance",
            "Humans",
            "Malaria",
            "Costs and Cost Analysis"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40775352/",
        "source_type": "Global"
    },
    {
        "pmid": "40770604",
        "title": "Optimization of pharmaceutical research and development by early-phase assessment of investigational medicinal products.",
        "abstract": "Small midsized pharmaceutical innovator often limited inhouse health economics market access expertise may struggle align development strategy investigational medicinal product health system need payer expectations Limited attention building health economic story early development phase may ultimately result suboptimal return investment Earlyphase health technology assessment eHTA provides structured approach value maximization Selection payment model help understand value proposition taken account general target payer new medicine Fair judgement degree innovation expected launch date essential choose relevant proposition general list value drivers Development conceptual value framework translates target product profile policyrelevant value propositions health gain expected cost saving avoided medical event delayed disease progression value use health system benefits Implementation health economics outcome research strategy help justify premium price based added value facilitate appropriate order target indication return investment Effective integration eHTA research development process enables innovator shorten time reimbursement increase probability clinical commercial success investigational medicinal products",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40770604/",
        "source_type": "Global"
    },
    {
        "pmid": "40768370",
        "title": "Investing in Infrastructure: A Mixed-Methods Cost Analysis of Implementation Strategies to Address Emerging Youth Drug Trends.",
        "abstract": "Schools engaged prevention effort struggle respond quickly effectively changing drug use trend due insufficient investment infrastructure local state national levels result preventable morbidity mortality among adolescents study estimated cost associated implementing Rapid Adaptation Prevent Drug use RAPD infrastructurebuilding implementation strategies using mixed method optimize data collection feasibility quality support comprehensive understanding outcomes conducted semistructured interview Step 1 prepilot trial inform initial cost data collection approach Step 2 used activitybased costing conducted sensitivity analysis estimated budget impact replication Step 3 included interview pilot participant contextualize result verify time reporting Thirtyfour school personnel participated Step 1 interview four health coordinator six teacher participated pilot study identified cost driver pragmatic constraint related effective timecost data collection developed activitybased costing data collection plan estimated cost deploying RAPD Step 2 6215school estimated budget impact replication 5551school 52 cost preimplementation phase Step 3 interview participant identified financial staffing resource central challenge infrastructure development study us mixed method approach including exploratory sequential design proactively guide microcosting identifying potential barrier advance enhanced rigor feasibility data collection process study offer preliminary cost estimate deploy RAPD infrastructurebuilding strategy address emerging drug trend sustain prevention efforts Building prevention infrastructure essential preventing onset escalation substance use among youth Implementation strategy key building robust implementation infrastructure prevention Estimating cost associated infrastructure building strategy vital realizing public health impact prevention interventions",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40768370/",
        "source_type": "Global"
    },
    {
        "pmid": "40767240",
        "title": "Assessment of Financial Impact of Expanding the Scope of Drug Usage in South Korea.",
        "abstract": "increasing utilization highcost drug multiple indication pose significant financial challenge healthcare system worldwide study evaluates financial impact expanding drug indication Korea focusing pharmaceutical expenditure trend study analyzed claim data National Health Insurance Service NHIS examine drug characteristic annual expenditure Interrupted timeseries analysis assessed monthly expenditure change following indication expansions analyzed 57 drug expanded indication 2012 2023 2012 2022 drug expenditure increased 15fold compound annual growth rate CAGR 308 significantly larger rise compared 19fold rise CAGR 65 total pharmaceutical expenditure covered NHIS Notably expenditure increased 35fold 35 drug classified anatomical therapeutic chemical ATC code L antineoplastic immunomodulating agents 375fold 26 drug risksharing agreement RSAs Interrupted timeseries analysis n  27 demonstrated significant monthly expenditure increase expansion US 033 million per month iPi000 significant increase expenditure pre postexpansion period US 499564 million iPi000 Moreover postexpansion trend showed significant additional increase expenditure US 013 million per month iPi003 24 month US 007 million per month iPi037 36 months Despite price reduction strategy multiindication drugs expenditure accelerated increase expenditure postexpansion indication highlight need robust postpricing management listed drugs long term total budget system could ensure predictable sustainable financing providing clear financial boundary within health insurance budget",
        "mesh_terms": [
            "Republic of Korea",
            "Humans",
            "Health Expenditures",
            "Drug Costs",
            "National Health Programs",
            "Interrupted Time Series Analysis",
            "Drug Utilization"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40767240/",
        "source_type": "Global"
    },
    {
        "pmid": "40767199",
        "title": "Impact of China's National Volume-Based Drug Procurement: A Multilevel Interrupted Time Series Analysis on Medical Expenditures in Hypertensive Patients.",
        "abstract": "National VolumeBased Procurement NVBP implemented China 2019 aim reduce patients economic burden lowering drug price promoting use NVBP drug public hospitals evaluated impact NVBP medical expenditure among hypertensive patients analyzing overall impact variation policy effect across individual hospitals Using medical record 117 million hypertensive patient across 82 hospital Tianjin 20172021 conducted interrupted time series analysis assess expenditure change among hypertensive patient treatment hypertension dyslipidaemia type 2 diabetes chronic ischemic heart disease IHD Multilevel model employed estimate overall impact hospitalspecific variation policy effects NVBP implementation significantly reduced pervisit outpatient expenditure among hypertensive patient treatment hypertension 1561 dyslipidaemia 2577 diabetes 1759 lowering drug expenditures Although drug expenditure chronic IHD decreased nondrug expenditure increased leading significant change total expenditure chronic IHD 897 inpatient expenditures significant change total peradmission expenditure observed chronic IHD diabetes hospitalizations Drug expenditure diabetes decreased significantly diagnostic expenditure increased significant change found chronic IHD drug expenditures individual hospital level significant variation policy effect observed Despite overall decrease outpatient expenditure treatment hypertension dyslipidaemia diabetes 456 672 463 hospitals respectively showed significant decreases remainder exhibited either nonsignificant change increases NVBP effectively reduced outpatient expenditure among hypertensive patient treatment hypertension dyslipidaemia diabetes suggesting potential alleviate patients economic burdens However increase nondrug expenditure substantial variation policy effect across hospital highlight room improvement policy implementation overall effectiveness",
        "mesh_terms": [
            "Humans",
            "Hypertension",
            "China",
            "Health Expenditures",
            "Interrupted Time Series Analysis",
            "Female",
            "Male",
            "Middle Aged",
            "Antihypertensive Agents",
            "Dyslipidemias",
            "Drug Costs",
            "Aged",
            "Diabetes Mellitus, Type 2",
            "Myocardial Ischemia",
            "Hospitals, Public"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40767199/",
        "source_type": "Global"
    },
    {
        "pmid": "40765838",
        "title": "Legal challenges to the 340B drug pricing program: administration, regulation, and reform.",
        "abstract": "340B Drug Pricing Program 340B Program created help safety net hospital clinic stretch scarce federal resources discounting price outpatient drug purchases spread discounted price sale price drug retained hospital clinics subsidizing operational cost funding service would otherwise possible provide 340B Program grown dramatically since inception eliciting significant criticism call reform Many legal challenge 340B Program agency tasked administering programthe Health Resources Services Administration HRSAhave brought highlighting limitation HRSAs powers Specifically HRSAs lack broad regulatory authority hampered ability oversee reform 340B Program article analyzes litigation challenging 340B Programincluding case regarding orphan drug exclusion definition 340B patient use contract pharmaciesand explores scope HRSAs authority regulate 340B Program so article emphasizes need reform ensure 340B Program operates consistent congressional purpose patient maintain access safety net care across country",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40765838/",
        "source_type": "Global"
    },
    {
        "pmid": "40761422",
        "title": "Revision of medicine prices and sales price evolution in Moroccan pharmacies.",
        "abstract": "Morocco adopted new medicine pricing policy 2013 introduced price revision following implementation Decree No 213852 study aim describe evolution medicine price decrease Moroccan pharmacy following price revision published Ministry Health part retrospective descriptive study price revision list five year 20142019 crossed database sale medicine sold pharmacies price decrease affected 1704 medicines 54 originator drugs therapeutic class involved 227 antiinfective 185 cardiovascular system Medicines public selling price 5 10 US dollar 254 affected drop even concerned price ranges 228 medicine decreased less equal 01 US dollar 287 recorded decrease less equal 1 public selling price Five medicine 03 reduced 70 732 maximum drop percentage following implementation Decree no 213852 series medicine price revision adopted price range therapeutic class affected price decrease several variations However complementary policy still needed improve access medicines",
        "mesh_terms": [
            "Morocco",
            "Humans",
            "Retrospective Studies",
            "Commerce",
            "Pharmacies",
            "Drug Costs",
            "Pharmaceutical Preparations"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40761422/",
        "source_type": "Global"
    },
    {
        "pmid": "40760754",
        "title": "Navigating Regulatory Complexities in Biosimilar Approvals and Imports for Autoimmune Disorder Management: A Comparative Analysis of FDA (US), EMA (EU), and CDSCO (India) Guidelines.",
        "abstract": "Biosimilars offer costeffective alternative autoimmune disorder treatment However Indias stringent regulatory barriers including mandatory local trials unclear interchangeability guidelines strict pricing controls hinder market access study conduct comparative analysis FDA US EMA EU CDSCO India regulatory frameworks highlighting key difference approval pathways postmarketing surveillance import regulations Unlike previous studies paper employ structured SWOT analysis assess impact Indias regulatory landscape biosimilar accessibility finding reveal Indias local clinical trial mandate complex approval process hinder biosimilar adoption despite prior FDA EMA approvals Additionally absence interchangeability guideline discourages physician confidence stringent pricing policy Drug Price Control Order DPCO reduce manufacturer incentives improve biosimilar market penetration India must streamline regulatory approvals harmonize clinical trial requirement international standards establish clear interchangeability guidelines reform essential enhance affordability accessibility biosimilars management autoimmune disorders",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40760754/",
        "source_type": "Global"
    },
    {
        "pmid": "40760733",
        "title": "Self-Reported Cannabis Prices and Expenditures From Legal and Illegal Sources Five Years After Legalisation of Non-Medical Cannabis in Canada.",
        "abstract": "price cannabis important implication many outcome discussed legalisation debates paper report legal illegal price different cannabis products National survey conducted 2022 2023 among Canadians aged 1665 year part International Cannabis Policy Study Selfreported price purchase quantity legal versus illegal source thelast cannabis purchased examined 2686 respondent used cannabis past 12 month nine cannabis product types average consumer report 78 cannabis came legal source past year Differences selfreported price paid legal illegal purchase varied product type Price per unit higher legal source dried flower 238 p  0001 vapes 187 p  0006 hash 384 p  0001 lower capsule 284 p  0008 statistically significant difference found drop 33 p  076 edible 39 p  049 cannabis drink 88 p  021 concentrate 138 p  015 tincture 170 p  028 Substantial quantity discount dried flower observed legal illegal sources Differences legal illegal cannabis price narrowed considerably likely due decline price cannabis legal store since opening legal market Canada difference expected across two market considering difference standard quantity purchased presence quantity discount markets Analyses omitting purchase quantity may overestimate price differential legal illegal sources",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40760733/",
        "source_type": "Global"
    },
    {
        "pmid": "40754325",
        "title": "Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID): protocol for a randomised controlled adaptive platform trial of treatments for acute SARS-CoV-2 infection in community settings.",
        "abstract": "SARSCoV2 endemic expected remain health threat new variant continuing emerge potential vaccine become less effective effective vaccine natural immunity significantly reduced hospitalisation need critical care outpatient treatment option remain limited realworld evidence clinical costeffectiveness lacking paper present design Canadian Adaptive Platform Trial Treatments COVID Community Settings CanTreatCOVID evaluating multiple treatment option pragmatic adaptive platform trial study generate highquality generalisable evidence inform clinical guideline healthcare decisionmaking CanTreatCOVID openlabel individually randomised multicentre national adaptive platform trial designed evaluate clinical costeffectiveness therapeutic nonhospitalised SARSCoV2 patient across Canada Eligible participant must present symptomatic SARSCoV2 infection confirmed PCR rapid antigen testing RAT within 5 day symptom onset trial target two group expected higher risk severe disease 1 individual aged 50 year older 2 aged 1849 year one comorbidities CanTreatCOVID us numerous approach recruit participant study including multifaceted public communication strategy outreach primary care outpatient clinic emergency departments Participants randomised receive either usual care including supportive symptombased management investigational therapeutic selected Canadian COVID19 Outpatient Therapeutics Committee first therapeutic arm evaluates nirmatrelvirritonavir Paxlovid administered two time per day 5 days second therapeutic arm investigates combination antioxidant therapy selenium 300 µg zinc 40 mg lycopene 45 mg vitamin C 15 g administered 10 days primary outcome allcause hospitalisation death within 28 day randomisation CanTreatCOVID master protocol subprotocols approved Health Canada local research ethic board participating province across Canada result study disseminated policymakers presented conference published peerreviewed journal ensure finding accessible broader scientific medical communities study approved Unity Health Toronto Research Ethics Board 22179 Clinical Trials Ontario Project ID 4133 NCT05614349",
        "mesh_terms": [
            "Humans",
            "COVID-19",
            "Canada",
            "SARS-CoV-2",
            "Cost-Benefit Analysis",
            "COVID-19 Drug Treatment",
            "Randomized Controlled Trials as Topic",
            "Adult",
            "Multicenter Studies as Topic",
            "Middle Aged",
            "Male",
            "Antiviral Agents"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40754325/",
        "source_type": "Global"
    },
    {
        "pmid": "40753662",
        "title": "Impact of the 2012 pharmaceutical co-payment reform on drug consumption among children in Catalonia: Evidence from a regression discontinuity design.",
        "abstract": "Poor childhood health negatively affect health socioeconomic status later life One crucial policy tool modification copayment conditions cause parent experience rigid budget constraint cause reduction number prescription drug given children study estimate price sensitivity prescription drug demand using data prescription drug purchase nonadult population Catalonia 2010 2015 use sharp regression discontinuity design RDD bandwidth exploiting 2012 reform Catalonia Spain result indicate overall reduction defined daily dose DDD consumption three year postreform child parent experienced increase copayment level 81  10  increase contrast whose parent experience reduction copayment rate 70 percentage point increase number prescription used corroborated finding considering drug stockpiling Interestingly prescription related female showed higher reduction males Disentangling drug consumption type condition show drug purchase related respiratory health condition experienced smaller reduction and specifically one associated asthma compared mental health disease AttentionDeficitHyperactivity Disorder evidence significant change overall drug consumption young people Spain following reform copayments",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40753662/",
        "source_type": "Global"
    },
    {
        "pmid": "40753376",
        "title": "Cost trends of potentially inappropriate medications among older adults between 2012 and 2021 in Quebec, Canada: a population-based repeated cross-sectional study.",
        "abstract": "Potentially inappropriate medication PIMs frequent older adults contributing hospitalizations adverse events healthcare burden aimed estimate direct PIM cost trend 2012 2021 among older woman men Quebec Canada Using medicoadministrative data assessed direct cost paid public insurer medication cost professional fee excluding outofpocket payment individuals PIMs claimed adult ≥65 year covered public drug plan Costs 16 PIM classes identified using 2015 2019 Beers criteria calculated stratified sex age group 6574 7584 ≥85 fiscal year assessed proportion PIMs among medication expenditures computed average costsenrollee usage prevalence costliest PIM classes Trends estimated using univariate linear regression 95 confidence intervals found nonstatistically significant decrease total PIM claim costs 206 million 2012 186 million 2021 trend 29174 116 representing 54 medication expenditure adult ≥65 2021 reduction total cost accentuated women whose annual cost higher men age groups Average costenrollee decreased 179 119 trend 719 5 drop 216 142 woman 132 92 men Costsenrollee higher 7584 ≥85 age groups Costliest PIM class included protonpump inhibitors benzodiazepines antipsychotics antidepressants estrogen women hypoglycemic agent men Cost trend always follow prevalence trend PIM classes PIM cost among older adult slightly decreased 2012 2021 Appropriate prescribing deprescribing appear crucial reducing costs research focus estimating societal impact costeffectiveness analysis deprescribing initiative regulatory measures",
        "mesh_terms": [
            "Humans",
            "Aged",
            "Female",
            "Male",
            "Cross-Sectional Studies",
            "Quebec",
            "Aged, 80 and over",
            "Potentially Inappropriate Medication List",
            "Inappropriate Prescribing",
            "Drug Costs",
            "Health Expenditures",
            "Population Surveillance"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40753376/",
        "source_type": "Global"
    },
    {
        "pmid": "40749000",
        "title": "Medical costs for patients with rheumatoid arthritis who have comorbid diabetes mellitus.",
        "abstract": "evaluate medical cost resource use patient rheumatoid arthritis RA without diabetes mellitus DM Data obtained Japan Medical Data Center JMDC claim database baseline period comprised 6 month index date first prescription date postRA diagnosis 12month duration postindex date followup period Patients RA DM prescribed antidiabetic drug baseline period constituted DM group patient RA without DM antidiabetic prescription baseline followup period belonged nonDM group Patients matched sex age Charlson Comorbidity Index CCI month first RA codes medications primary endpoint total medical cost per patient followup period secondary endpoint cost drugs treatments materials subcategories proportion patient using subcategories One hundred sixtyone DM group patient 2974 nonDM group patient eligible inclusion 109 patient matched group median value age CCI 59 year 20 groups excluding DMspecific costs total medical cost drug cost significantly higher DM group compared nonDM group total medical costs DM nonDM 5163 USD 3782 USD P  005 drug costs DM nonDM 2242 USD 1066 USD P  005 higher proportion biological diseasemodifying antirheumatic drug DMARD user DM group DM nonDM 147 55 Treatment cost material cost differ two groups Medical cost RA higher DM group nonDM group higher proportion biological DMARD users",
        "mesh_terms": [
            "Humans",
            "Arthritis, Rheumatoid",
            "Female",
            "Male",
            "Middle Aged",
            "Aged",
            "Health Care Costs",
            "Comorbidity",
            "Diabetes Mellitus",
            "Japan",
            "Hypoglycemic Agents",
            "Adult",
            "Antirheumatic Agents"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40749000/",
        "source_type": "Global"
    },
    {
        "pmid": "40744435",
        "title": "Estimates of first-year OTC naloxone sales in four U.S. states with high rates of opioid overdose deaths: KY, MA, NY, OH.",
        "abstract": "March 2023 US Food Drug Administration approved naloxone nasal spray overthecounter OTC sale creating directtoconsumer path increase access utilized weekly NielsenIQ NIQ retail sale data OTC naloxone local area within Kentucky KY Massachusetts MA New York NY Ohio OH week ending 992023 week ending 4272024 sale occurring physical store eg grocery pharmacy analyzed percentage store selling average price per kit sales assessed pattern local sale Social Deprivation Index accounting poverty housing transit education employment brand Narcan made approximately 99  recorded OTC naloxone sale September 2023 April 2024 Weekly sale OTC naloxone KY MA NY OH spiked initially September October 2023 stabilized April 2024 average price per OTC naloxone kit 45 across state brand 50  86  NIQ participating store state sold OTC naloxone large proportion local area three state demonstrated high social deprivation low OTC naloxone sales OTC naloxone increase access though price may deter people low income evidenced finding lower sale among area high social deprivation emphasizing importance naloxone access laws opioid education naloxone distribution programs Medicaid coverage OTC naloxone creates new channel market penetration satisfying previously untapped demand support naloxone saturation",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40744435/",
        "source_type": "Global"
    },
    {
        "pmid": "40741379",
        "title": "Copay Accumulators: A Legislative Issue in Dermatology.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40741379/",
        "source_type": "Global"
    },
    {
        "pmid": "40740994",
        "title": "Pakistan's first medicine price deregulation policy: assessing its impact on prices, affordability, and availability of oral anti-diabetic medicines in private pharmacies.",
        "abstract": "Pakistans highest diabetes prevalence necessitates equitable access antidiabetic medicines study evaluated access Oral antidiabetic OADs effect Pakistans recently launched price deregulation policyapplicable medicine included National Essential Medicines List nonNEMLon price affordability comparing NEML nonNEML OADs WHOHAI methodologybased survey 30 private pharmacy across six region gathered price availability data 30 OADs including Lowest Price Generic LPG Highest Price Generic HPG originator brand OB selected OADs consisted 11 product NEML 19 nonNEML products comprising 17 singleactive ingredient 13 multiactive ingredient formulations Published surveyed retail price OADs in Pakistani Rupees PKR deregulation compared policys effect determined differenceindifferences DiD analysis Affordability lowestpaid employee medicine availability percentage calculated analysis revealed unit price OADs significantly increased PKR 1508 OB PKR 589 HPG PKR 281 LPG ipi  005 within 6 month policys introduction Medicines listed NEML remained consistently cheaper nonNEML difference 3020 OBs 983 HPGs 751 LPGs PKR ipi  0001 per interaction term NEML enlistment status × deregulation greater increase price nonNEML OBs observed compared NEML counterpart PKR 1085 ipi ≈ 005 difference observed LPGs PKR 077 ipi  073 HPGs PKR 020 ipi  095 insignificant Prices single multiactive ingredient formulation also increased significantly ipi  005 Although OADs fair availability 47 97 deregulation seven 30 OADs remained unaffordable time points overall affordability declined significantly postderegulation ipi  005 study revealed significant price escalation OADs particularly enlisted NEML highlighting access challenge diabetic patient necessitating targeted policy reform address key marketrelated factor ensure equitable access OADs",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40740994/",
        "source_type": "Global"
    },
    {
        "pmid": "40740949",
        "title": "Spending, utilization, and price trends for anti-obesity medications in U.S. Medicaid programs: an empirical analysis from 1999 to 2023.",
        "abstract": "Obesity pose significant public health economic challenge United States US rising prevalence particularly among individual enrolled Medicaidthe nations public health insurance program lowincome populations Antiobesity medication AOMs become integral managing obesity trend utilization spending within Medicaid remain underexplored examine Medicaids utilization reimbursement price trend AOMs 1999 2023 retrospective analysis assessing utilization reimbursement pricing older newer AOMs Yearly prescription number reimbursement calculated seven AOMs billed Medicaid 1999 2023 average expenditure per prescription used indicator drug pricing AOM prescription rose 13855 1999 938663 2023 6674 increase Spending surged 77805466 due introduction newer effective medications including Wegovy tirzepatide largest share market growth 2023 driven medications significant increase AOM utilization spending highlight growing burden obesity Medicaid emphasizing need policy measure manage rising cost ensure equitable access treatment",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40740949/",
        "source_type": "Global"
    },
    {
        "pmid": "40739691",
        "title": "The Economics of Drug Development: A Comparison Between Orphan and Non-Orphan Drugs.",
        "abstract": "Drug development cost orphan nonorphan drug range greatly variation market size legal constraints financial incentives order overcome tiny patient population high perpatient costs orphan drug target rare disease frequently need customized techniques Since nonorphan drug intended larger populations require thorough clinical trial fierce rivalry market Clinical trial data orphan nonorphan drug authorized 2010 2020 compared term cost study Trial duration overall development expenditures perpatient cost important criteria estimate cost components secondary data source industry report regulatory filing consulted Significant cost driver variation found using statistical analysis study show orphan pharmaceutical generally lower overall clinical development costs cost per patient much higher nonorphan drugs Financial incentive including tax credit accelerated regulatory process helped orphan drug trial save money overall However nonorphan drug required extensive safety efficacy evaluation larger Phase III trials cost higher study emphasizes orphan nonorphan drug different clinical cost structure economic tradeoffs necessity sustainable financing option highlighted high cost per patient even regulatory incentive successfully lower barrier orphan drug research economic impact drug research cost various stakeholders including drug companies physicians lawmakers enables make sound choice regarding resource allocation investment drug development Policymakers industry stakeholder use data help create fair effective framework drug development",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40739691/",
        "source_type": "Global"
    },
    {
        "pmid": "40739256",
        "title": "Economic evaluation of a robotic chemotherapy compounding system and its service expansion to network hospital in Thailand.",
        "abstract": "Robotic system chemotherapy preparation offer improved accuracy staff safety require substantial capital investment study assessed economic performance domestically developed robotic chemotherapy compounding system Udon Thani Cancer Hospital service expansion network hospital Thailand descriptive study economic evaluation conducted including costbenefit analysis unit cost analysis breakeven analysis provider health system perspectives Data fiscal year 2023 used Direct indirect cost assessed clinical outcome documented scenariobased sensitivity analysis performed examine cost variation different capacity utilisation levels Robotic preparation higher perdose cost THB 538 4173 doses manual preparation THB 250 20310 doses associated total estimated economic benefit THB 188 million including labour training saving improved pharmaceutical care breakeven point estimated 41802 dos robotic compounding 5122 dos service expansion incremental benefitcost ratio IBCR 1566 increased 3018 including delivery network hospital robotic system demonstrated potential economic operational advantages particularly scaled serve additional facilities finding offer preliminary evidence inform future policy consideration Thailands Cancer Service Plan evaluation needed assess longterm sustainability broader systemlevel outcomes",
        "mesh_terms": [
            "Thailand",
            "Humans",
            "Cost-Benefit Analysis",
            "Robotics",
            "Drug Compounding",
            "Antineoplastic Agents"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40739256/",
        "source_type": "Global"
    },
    {
        "pmid": "40735811",
        "title": "'Industry still has too loud a voice': expert views on government policy consultations about gambling marketing.",
        "abstract": "Marketing part suite tactic used gambling industry ally promote normalize gambling increased public call restriction gambling marketing government developed comprehensive policy response counter public health threat Consultation process widely seen important part public decisionmaking policy formation However limited focus process gambling policy development Using online qualitative survey study gathered opinion 33 expert Australia UK USA including local governments academia profits lived experience organizations consultation process related gambling marketing policy current process could improved reflexive approach thematic analysis used construct three theme data First participant perceived current consultation process inconsistent public health value approach limited meaningful opportunity community actor shape strengthen policy response gambling marketing Second participant stated consultation practice prioritized industry view concerns industry actor and allies disproportionate access policymakers decisionmakers Finally participant commented mechanism ensure policy development related gambling marketing protected vested interests paper provides new information factor influence policy decision gambling marketing Mechanisms protect policy vested interest essential developing comprehensive public health response gambling marketing",
        "mesh_terms": [
            "Gambling",
            "Humans",
            "Marketing",
            "Australia",
            "Policy Making",
            "Public Policy",
            "United States",
            "United Kingdom",
            "Qualitative Research",
            "Public Health",
            "Health Policy",
            "Surveys and Questionnaires",
            "Decision Making"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40735811/",
        "source_type": "Global"
    },
    {
        "pmid": "40732312",
        "title": "Bridging the Regulatory Divide: A Dual-Pathway Framework Using SRA Approvals and AI Evaluation to Ensure Drug Quality in Developing Countries.",
        "abstract": "bBackgroundb Developing country face significant challenge accessing highquality pharmaceutical product due resource constraints limited regulatory capacity market dynamic often prioritize cost quality review address critical gap regulatory framework fail ensure pharmaceutical quality equity developed developing nations bObjectiveb comprehensive review examines novel dualpathway regulatory framework leverage stringent regulatory authority SRA approvals artificial intelligencebased evaluation systems harmonized pricing mechanism ensure pharmaceutical quality equity across global markets bMethodsb comprehensive systematic analysis current regulatory challenges proposed solutions implementation strategy conducted extensive literature review 202 sources 20192025 expert consultation regulatory science AI implementation healthcare pharmaceutical policy development methodology included analysis regulatory precedents economic impact assessment feasibility evaluation based existing technological implementations bResultsb proposed framework address key regulatory capacity gap two complementary pathways Pathway 1 enables samebatch distribution SRAapproved product pricing parity mechanisms time Pathway 2 provides independent evaluation using AIenhanced system differentiated products Key component include indigenous AI development requires systematic implementation 46 year across three distinct stages outsourced auditing framework reduce cost 4050 qualityfirst principle categorically reject costbased quality compromises Implementation analysis demonstrates potential achieving 9095 quality standardization accompanied 200300 increase regulatory evaluation capability bConclusionsb framework potential significantly improve pharmaceutical quality access developing country maintaining rigorous safety efficacy standard innovative regulatory approaches evidence demonstrates substantial public health benefit projected improvement population access 8595 coverage treatment success rate 9095 efficacy economic benefit USD 1530 billion system efficiencies providing compelling case implementation aligns global scientific consensus Sustainable Development Goal 38",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40732312/",
        "source_type": "Global"
    },
    {
        "pmid": "40730420",
        "title": "Financial protection and universal health coverage in Georgia: an analysis of impoverishing healthcare costs using household income and expenditure surveys .",
        "abstract": "Financial protection important objective universal health coverage ensures individual access necessary healthcare without financial hardship typically assessed two indicators catastrophic outofpocket OOP health spending impoverishing health spending Despite introduction Georgias Universal Health Coverage Programme UHCP 2013 cover nearly 90 population incidence impoverishing catastrophic health spending remains high compared European country changed much past decade study aim identify factor associated impoverishing health expenditure among Georgian household inform financing policy decision prevent individual driven deeper poverty due healthcare costs used data Georgian Household Income Expenditure Surveys spanning 20092023 n198 292 households surveyweighted logistic regression accounted complex design element stratification clustering unequal selection probabilities outcome variable impoverishing health spending defined using relative poverty line Andersens behavioural model healthcare utilisation guided explanatory variable selection OOP spending drug strongest determinant impoverishment OR 433 95 CI 393 477 p0001 poorest quintile especially burdened OR 445 95 CI 221 897 p0001 second quintile also elevated risk odds impoverishment declined 2009 2013when benefit targeted poorbut rose slightly afterwards 2014 2023 average probability impoverishment around 034 compared 028 2013 finding suggest targeted benefit UHCP may offered stronger protection broader less targeted approach post2013 Enhanced coverage outpatient drug costsespecially poorestthrough increased public investment progressive benefit expansion could improve financial protection",
        "mesh_terms": [
            "Humans",
            "Health Expenditures",
            "Universal Health Insurance",
            "Georgia (Republic)",
            "Poverty",
            "Female",
            "Male",
            "Adult",
            "Income",
            "Middle Aged",
            "Financing, Personal",
            "Family Characteristics",
            "Surveys and Questionnaires"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40730420/",
        "source_type": "Global"
    },
    {
        "pmid": "40729790",
        "title": "Pregabalin and gabapentin use in France from 2012 to 2023, impact of prescription restrictions, a time series analysis.",
        "abstract": "Gabapentinoids use accompanied increased misuse particularly pregabalin May 2021 France introduced secure prescription requirement pregabalin paper aim analyse variation gabapentinoid dispensing focus change prescription rules performed ecological study using French national health insurance database January 2012 December 2023 analysed pregabalin gabapentin dos sold city pharmacy expressed monthly defined daily dose per thousand inhabitant day DDDTID January 2012 December 2023 Dose sale trend May 2021 compared using segmented analysis Autoregressive Integrated Moving Average models Descriptive analysis performed analyse associated expense expressed euros 2012 2020 pregabalin dos sold rose 3228 DDDTID 4908 DDDTID reform declined 3923 DDDTID 2023 Gabapentin dos sold increased 1042 DDDTID 1257 DDDTID 2012 2020 rose postreform reaching 1705 DDDTID Costs related pregabalin dos sold decreased €13247 €5136 million 2012 2023 Costs related gabapentin decrease €3231 €2684 million 2012 2021 increase €3770 million 2023 data suggest May 2021 reform reduced pregabalin consumption induced increase gabapentin use Cost implication remain difficult interpretation due multiple confounding factors research could clarify trend used optimize prescription practices",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40729790/",
        "source_type": "Global"
    },
    {
        "pmid": "40721270",
        "title": "Effect of universal no-cost coverage on use of long-acting reversible contraception and all prescription contraception: population based, controlled, interrupted time series analysis.",
        "abstract": "estimate effect policy introducing universal nocost public coverage prescription contraception use British Columbia Canada Population based controlled interrupted time series analysis 10 Canadian provinces Prescription medication dispensed reproductive aged 1549 years female resident British Columbia Canada compared synthetic control derived nine Canadian province population based cohort 859 845 female individual British Columbia age 1549 years 1 April 2021 30 June 2024 Introduction universal contraception coverage policy April 2023 public insurer pay 100 prescription costs Number monthly dispensation longacting reversible contraception LARC number monthly dispensation form prescription contraception including LARC percentage reproductive aged female resident using LARC using form prescription contraception proportion people using prescription contraception use LARC LARC market share Segmented regression model used estimate policy effect comparing expected outcome value 15 month policy ie counterfactual derived trend policy change control observed values 95 confidence interval CIs estimated using bootstrapping April 2021 3249 95 CI 3066 3391 LARC prescription dispensed British Columbia declining slope trend 17 30 7 fewer dispensed per month policy Monthly LARC dispensation increased 1050 942 1487 immediately British Columbias policy change saw steady increasing trend policy introduction additional 1273 963 1698 monthly LARC prescription dispensed 15 month policy implementation compared expected volume representing estimated 149fold 134 177 increase Dispensations prescription contraception including LARC increased 1981 356 3324 per month representing 104fold 101 107 increase Among 859 845 female resident aged 1549 year population 91 using LARC April 2021 15 month policy 11 375 10 273 13 013 individual using LARC expected without policy representing additional 13 12 15 population policy led additional 17 15 23 population using prescription contraception 15 month policy LARC market share 19 12 23 higher expected Universal nocost public coverage British Columbia increased prescription contraception use overall driven increased LARC use such cost seems important contributor contraception use method selection population level",
        "mesh_terms": [
            "Humans",
            "Female",
            "Adult",
            "Interrupted Time Series Analysis",
            "Adolescent",
            "Long-Acting Reversible Contraception",
            "British Columbia",
            "Young Adult",
            "Middle Aged",
            "Contraception",
            "Universal Health Insurance"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40721270/",
        "source_type": "Global"
    },
    {
        "pmid": "40716340",
        "title": "Moralisation, stigmatisation, and downstream interventions: How symbolic violence sustains geographic inequalities in deaths of despair in England.",
        "abstract": "paper examines symbolic violence contributes persistence geographic inequality death despair DoD drug suicide alcoholspecific mortality two deindustrialised town North East England Although evidence DoD driven structural determinants economic policies inadequate social safety nets poverty less known determinant ideologically obscured Drawing qualitative data collected 30 resident Middlesbrough South Tyneside two town average rate DoD analysis explores symbolic violence form moralisation stigma downstream interventions frame behaviour individual failings downplays structural determinants sustains inaction maintaining appearance intervention diverting attention away root cause DoD symbolic violence function mechanism inequality reproduced highlighting cultural ideological process allow structural determinant go unaddressed study deepens understanding inequality death sustained legitimised marginalised places finding point need future intervention improve material condition also critically engage symbolic force reinforce geographic disparity DoD",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40716340/",
        "source_type": "Global"
    },
    {
        "pmid": "40716165",
        "title": "The associations between prices and taxes and the use of tobacco products in Latin America and the Caribbean: a systematic review and meta-analysis.",
        "abstract": "Although tax raise retail tobacco price industryinitiated price increase shown decrease tobacco consumption scarcity study Latin America Caribbean using household individuallevel data existing review limit policy relevance conduct systematic review metaanalysis assess association price tax use tobacco product Latin America Caribbean searched six electronic bibliographic databases two online search engines two working paper repositories handsearched seven journals included quantitative study used measure individual household tobacco use outcome written English Portuguese Spanish used randomeffects metaanalyses pool result across studies found consistent evidence Latin American countries higher cigarette price associated lower cigarette smoking participation consumption initiation effect size large enough policy meaningful Pooled ownprice elasticity indicate higher price associated less proportional decrease tobacco use pooled ownprice elasticities participation 014 95 CI 022 006 consumption 054 95 CI 075 034 total 075 95 CI 114 036 found consistent evidence socioeconomic status age sex rurality geographic region affected price responsiveness review confirms tax raise tobacco price effectively lower tobacco use Moreover raising tobacco price increased tax anticipated boost tax revenue due inelastic nature demand tobacco",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40716165/",
        "source_type": "Global"
    },
    {
        "pmid": "40720104",
        "title": "Reducing Drug Prices-The Most Favored Nation Policy vs Price Negotiation.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40720104/",
        "source_type": "Global"
    },
    {
        "pmid": "40720101",
        "title": "The Role of Combination Drugs in the Medicare Drug Price Negotiation Program.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40720101/",
        "source_type": "Global"
    },
    {
        "pmid": "40717766",
        "title": "What drug characteristics explain the wide range of manufacturer rebates?",
        "abstract": "Prescription drug list prices often cited policy discussions account rebate negotiated manufacturer payers study examines factor influencing rebate United States focusing specialty drugsie high priced therapy often biologics payer issue specific coverage policies Rebate data came SSR Health drug attribute Tufts Medical Center Specialty Drug Evidence Coverage Database stratified rebate data drug type characteristics identified 161 drug found SSR Health SPEC December 2023 found rebate vary substantially across drug median 27 IQR 1653 Biosimilar originator drug highest variable rebate median 71 IQR 5379 rebate cancer treatment orphan drug lower medians 19 23 respectively vary less IQR 1228 1429 respectively Drugs face competition alternative option within therapeutic class selfadministered received Food Drug Administration approval past higher rebates finding indicate rebate sizeable vary along several dimensions many relating market competition complicating policy discussion around drug pricing",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40717766/",
        "source_type": "Global"
    },
    {
        "pmid": "40717765",
        "title": "Research and development investments for biologics independently developed by US biotechnology startups, 2017-2023.",
        "abstract": "Despite policy interest pharmaceutical innovation little known investment needed venture capitalbacked startup develop innovative biologics growing segment pharmaceutical marketplace crosssectional analysis Food Drug Administration FDA drug approval data investment deal records clinical trial data estimated investment needed biotechnology startup company independently develop biologic approved US FDA priority review indicator innovation isolate homogenous set cases sample focused independent drug development 13 drug 9 biotechnology startup company retained ownership drug start development FDA approval without acquired licensing product found median investment per FDAapproved biologic 3041 million IQR 28997903 million uncapitalized costs accounting cost failures estimate represents direct drug RD investment needed independent development innovative biologic product biotechnology startup companies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40717765/",
        "source_type": "Global"
    },
    {
        "pmid": "40713845",
        "title": "Efficiency in health care: connecting economic evaluations with implementation objectives.",
        "abstract": "Economic evaluation helpful efficient resource use paper aim clarify relationship economic evaluation method two type health care efficiency aiding implementation scientist selecting appropriate approach research clarify connection costeffectiveness analysis CEA allocative efficiency explain budget impact analysis BIA closely connects productive efficiency also discus method researcher use analyze organizations productive efficiency given increasing pressure health care organization efficient Allocative efficiency seek maximize social welfare optimal resource distribution Productive efficiency focus organizations ability maximize output given resource constraints CEA particularly incorporating societal perspective assesses allocative efficiency BIA often short time horizon focused perspective assesses productive efficiency organizational leader ask implementation scientist economic evaluation important determine whether want CEA BIA given answer different questions often employing different methods also present method measuring efficiency cause inefficiency stemming fixed costs scale scope regulations labor decisionmaking Implementation scientist must recognize CEA BIA serve distinct purpose interchangeable Choosing right economic evaluation tool crucial answering specific research question building research teams Future implementation work also need measure efficiency sustainable",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40713845/",
        "source_type": "Global"
    },
    {
        "pmid": "40712615",
        "title": "Clinical impact and cost-effectiveness of the WHO-recommended advanced HIV disease package of care.",
        "abstract": "subSaharan Africa 2040 people living HIV present advanced HIV disease AHD diagnosed treated prevented using package care recommended WHO aimed project costeffectiveness budget impact WHOrecommended AHD package Malawi Using CostEffectiveness Preventing AIDS ComplicationsInternational model simulated cohort nonhospitalised people living HIV aged 19 years initiating antiretroviral therapy ART 25 AHD CD4 count 200 cell per μL andor stage 3 4 disease assessed 13 increasingly comprehensive strategies ranging ART WHOrecommended AHD package including tuberculosis diagnostics ie sputum Xpert urine lipoarabinomannan tuberculosis preventive therapy serum cryptococcal antigen CrAg screening preemptive fluconazole treatment CrAgpositive cotrimoxazole prevent bacterial infections Model outcome included 1 year survival life expectancy costs incremental costeffectiveness ratio ICERs US per qualityadjusted lifeyear QALY considered strategy costeffective ICER less 600 per QALY based 2023 Malawi per caput gross domestic product ART resulted life expectancy 17·45 undiscounted QALYs discounted lifetime cost 1450 strategy would increase QALYs costs WHOrecommended AHD package would result greatest life expectancy 19·30 undiscounted QALYs costeffective ICER 580 per QALY AHD prevalence intervention efficacy greatest influence ICERs however WHOrecommended AHD package would remain costeffective wide range estimates WHOrecommended AHD package care ART initiation would provide substantial clinical benefit costeffective Malawi package AHD made widely available Malawi similar settings WHO HIV Modelling Consortium within Institute Global Health University College London Bill  Melinda Gates Foundation National Institute Allergy Infectious Diseases Massachusetts General Hospital Jerome Celia Reich Endowed Scholar HIVAIDS Research Award Steve Deborah Gorlin Massachusetts General Hospital Research Scholars Award Chichewa translation abstract see Supplementary Materials section",
        "mesh_terms": [
            "Humans",
            "Cost-Benefit Analysis",
            "HIV Infections",
            "Malawi",
            "World Health Organization",
            "Male",
            "Adult",
            "Female",
            "Quality-Adjusted Life Years",
            "Tuberculosis",
            "Anti-HIV Agents"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40712615/",
        "source_type": "Global"
    },
    {
        "pmid": "40709376",
        "title": "Economic evaluation of oral Nirmatrelvir/ritonavir versus best supportive care in patients at high risk for progression to severe COVID-19 in Germany: a cost-effectiveness analysis.",
        "abstract": "estimate costeffectiveness Nirmatrelvirritonavir NMVr versus best supportive care BSC patient highrisk progression severe COVID19 German health payer perspective closed cohort static model 1000 COVID19 patient capturing shortterm 1 year iviai decisiontree longterm lifetime outcome iviai Markov model used assess costeffectiveness NMVr versus BSC Model input derived EPICHR clinical trial published contemporary realworld data Probabilistic deterministic sensitivity analysis PSA DSA conducted test robustness model results base case treatment NMVr versus BSC reduced COVID19 related hospitalisation 0042 intensive care unit admission 0006 inpatient death 0003 increasing lifeyears LY 0047 per patient result incremental costeffectiveness ratio 10845 € per hospitalisation avoided 9773 € per LY gained Sensitivity analysis suggests magnitude benefit increased increasing hospitalisation risk NMVr emerged dominant strategy population hospitalisation risk equivalent 60 year older Outcomes similar real world effectiveness data DSA showed model sensitive hospitalisation inpatient mortality risk NMVr medication cost efficacyeffectiveness NMVr reducing hospitalisation PSA confirmed robustness model results COVID19 dynamic disease caution taken generalizing results Contemporary data essential ensure model input outcome remain relevant may change natural disease course effectiveness NMVr costeffectiveness analysis NMVr treatment German healthcare payer perspective demonstrates preventing progression severe COVID19 NMVr reduces healthcare resource use associated cost preserve LY patients analysis provides crucial economic rationale decision making policy makers",
        "mesh_terms": [
            "Germany",
            "Humans",
            "Male",
            "Female",
            "Middle Aged",
            "Aged",
            "Cost-Effectiveness Analysis",
            "Antiviral Agents",
            "COVID-19",
            "COVID-19 Drug Treatment",
            "Decision Trees",
            "Markov Chains",
            "Hospitalization",
            "Disease Progression",
            "Risk Factors",
            "Clinical Trials as Topic",
            "Sensitivity and Specificity",
            "Intensive Care Units",
            "SARS-CoV-2",
            "Quality-Adjusted Life Years",
            "Cost-Benefit Analysis",
            "Palliative Care",
            "Lactams",
            "Ritonavir",
            "Drug Combinations",
            "Nitriles",
            "Proline",
            "Leucine"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40709376/",
        "source_type": "Global"
    },
    {
        "pmid": "40709284",
        "title": "The cost of misaligned incentives in the pharmaceutical supply chain.",
        "abstract": "Recent concern rising drug price focused role pharmacy benefit manager PBMs multiple player make pharmaceutical supply chain PBMs conductor effectively decide drug covered cost PBM contract tie compensation percentage drugs list price creating financial incentive favor highcost highrebate drug plan formulary expense lowercost generic biosimilars Furthermore PBM industry highly concentrated vertically integrated countrys largest health insurers making even harder assess PBM performance profitability simple analysis annual drug spending different reporting level provides important insight money go saving could achieved find simply delinking compensation list price drug throughout supply chain could reduce annual drug spending 95b nearly 15 net spending without adversely affecting manufacturers incentive innovate",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40709284/",
        "source_type": "Global"
    },
    {
        "pmid": "40708038",
        "title": "Are there differences in efficacy and safety between local and imported direct-acting antiviral agents for hepatitis C in China?",
        "abstract": "Despite price advantages local directacting antiviral agent DAAs hepatitis C hep C widely used China compared imported ones evidence relative efficacy safety whether small market share local DAAs attributable potential differences study systematically evaluated efficacy safety evidence 5 local 6 imported DAAs valid Chinese registration number January 25 2024 Metaanalyses subgroup analysis metaregressions performed synthesize evidence compared outcome using randomeffects empirical Bayes model Nineteen randomized controlled trial 82 singlearm trial SATs included result demonstrated statistically significant difference 12week sustained virological response 097 95 confidence interval CI 095 099 v 096 95 CI 094 098 P  021 relapse 002 95 CI 001 004 v 002 95 CI 001 003 P  065 virological breakthrough 0003 95 CI  0001 002 v 00000002 95 CI  0001 00006 P  051 serious adverse event SAEs 004 95 CI 003 006 v 003 95 CI 002 003 P  012 local imported DAAs controlling ethnicity patient multiple metaregression local DAAs 337 higher rate adverse event AEs 0337 95 CI 0188 0486 P  0001 statistically significant difference found interaction test local imported pangenotypic DAAs regarding rate AEs 072 95 CI 064 079 v 073 95 CI 065 050 P  081 Current evidence demonstrates statistically significant difference efficacy SAEs local imported DAAs Given simplified pangenotypic DAA regimen standard care local pangenotypic DAAs hold potential increase hepatitis C virus treatment rate China critical local DAA developer generate evidence expanded patient population term age treatment experience genotype hepatitis C virus conducting headtohead study directly comparing efficacy safety Clinical policy decisionmaking adaptive evolve new evidence generated",
        "mesh_terms": [
            "Humans",
            "China",
            "Antiviral Agents",
            "Hepatitis C",
            "Hepacivirus",
            "Treatment Outcome",
            "Randomized Controlled Trials as Topic"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40708038/",
        "source_type": "Global"
    },
    {
        "pmid": "40707087",
        "title": "Enhancing tuberculosis care in Madhya Pradesh through public-private partnerships: An evaluation of the patient provider support agency (PPSA) model.",
        "abstract": "quality care patient receive private sector reported poor Madhya Pradesh began adopting PPSA model September 2020 initially covering 44 districts April 2022 state achieved 100 coverage becoming first state country implement PPSA across 52 districts Although PPSA operational every district health indicator private sector shown little improvement notification private sector remain significantly annual target patient provider support agency PPSA pilot program demonstrated newer strategy private sector engagement able deliver significant outcomes study explores strength limitation private sector engagement model healthcare providers perspective mixedmethods study quantitative qualitative data simultaneously collected Quantitative data collection using routinely collected programmatic data supported qualitative data collection indepth interviews study conducted study impact PPSA service implementation model notification status patient care activity outcome record review among 52 district Madhya Pradesh October 2020December 2022 well explore strength limitation PPSA model healthcare providers perspective using mixedmethods approach increase number TB patient notified private sector 62 number patient receiving benefit Nikshay Poshan Yojna Direct Bank Transfer 91 number patient tested Human Immunodeficiency Virus 100 Diabetes universal drug susceptibility testing 25 well successful treatment outcome postPPSA period compared prePPSA period Seventeen indepth interview health care provider public n  8 private sector n  9 highlighted operational challenge solution implementation PPSA Inadequate Human resource poor coordination NTEP Staff poor mapping PPs mobile based counselling  limited home visit TB patient perceived challenge regular support private health facility MIS data training handholding supportive supervision State strict need based tendering policy suggestion improve PPSA model solutions implementation Patient Provider Support Agency PPSA model Madhya Pradesh improved notification rate successful treatment outcome also strengthened overall engagement private healthcare provider TB management Enhanced collaboration regular facility mapping sustained educational effort led robust approach TB care extends across public private sectors challenge funding inconsistency service delivery fluctuation highlight area improvement overall success PPSA model Madhya Pradesh provides promising framework region aiming enhance TB care publicprivate partnerships Future effort focus addressing identified gap scaling successful practice ensure highquality care TB patients irrespective seek treatment",
        "mesh_terms": [
            "Humans",
            "India",
            "Public-Private Sector Partnerships",
            "Tuberculosis",
            "Health Personnel",
            "Private Sector",
            "Quality of Health Care"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40707087/",
        "source_type": "Global"
    },
    {
        "pmid": "40705731",
        "title": "Understanding insurance coverage policies for incretin mimetics for weight management.",
        "abstract": "Given wide variation insurance coverage incretin mimetics weight management IMWM US aimed understand 1 coverage policy IMWM influencing factors 2 coverage policy weight management treatments 3 opportunity support weight management constraining health care costs Qualitative study Participants leader highlevel employee large health insurance organization US aim survey 20 participants 10 organization covered IMWM 10 excluded coverage IMWM Participants completed 30minute interview Interviews audio recorded transcribed verbatim analyzed using directed content analysis Twenty individual completed interview 9 interviewee organization covered IMWM time study 11 organization excluded coverage IMWM identified 5 key themes 1 high cost primary barrier coverage IMWM 2 perception obesity lifestyle choice 3 current planned use varied utilization management strategy limit initial ongoing prescribing IMWM 4 coverage lifestylechange program support weight management 5 perceived responsibility pharmaceutical company lower list price IMWM enable broad coverage advance health equity High cost IMWM primary limiting factor coverage policies variability plan design utilization management strategy aim reduce nearterm spending Health plan leader call pharmaceutical company reduce list price increase equitable access IMWM",
        "mesh_terms": [
            "Humans",
            "Insurance Coverage",
            "United States",
            "Incretins",
            "Male",
            "Female",
            "Qualitative Research",
            "Obesity",
            "Middle Aged",
            "Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40705731/",
        "source_type": "Global"
    },
    {
        "pmid": "40705178",
        "title": "Cost-effectiveness of benmelstobart-anlotinib-chemotherapy in extensive-stage small-cell lung cancer: A comparative analysis across United States and Chinese healthcare systems.",
        "abstract": "Benmelstobart anlotinib plus etoposidecarboplatin EC group demonstrated substantial clinical efficacy improving survival outcome patient extensivestage smallcell lung cancer ESSCLC However high treatment cost raise concern regarding affordability costeffectiveness across healthcare system heterogeneous pricing reimbursement mechanisms study aimed evaluate costeffectiveness benmelstobart anlotinib plus EC group compared EC alone group anlotinib plus EC group US Chinese payer perspectives finding intended inform valuebased pricing strategy evidencebased reimbursement decisionmaking partitioned survival model PSM lifetime horizon 21day cycle constructed using clinical data ETER701 trial Direct medical cost health utility input obtained national databases local hospitals published literature primary outcome incremental costeffectiveness ratio ICER calculated comparing cost qualityadjusted life year QALYs treatment strategies Scenario analyses including drug price simulation deterministic probabilistic sensitivity analyses conducted evaluate model robustness Willingnesstopay WTP threshold set 100000QALY 150000QALY US 40011QALY China US benmelstobart anlotinib plus EC group yielded ICER 12156040QALY versus EC alone group 12757909QALY versus anlotinib plus EC group 150000QALY threshold However 100000QALY threshold costeffectiveness would require reducing benmelstobarts price 131612600 mg China ICER 11766717QALY exceeded local threshold Price simulation suggested costeffectiveness could achieved price reduced 223060600 mg US 32847600 mg China Sensitivity analysis identified progressionfree survival PFS utility benmelstobart pricing major cost drivers Probabilistic analysis indicated 751 probability costeffectiveness 150000QALY US However probability costeffectiveness 0 WTP threshold 100000QALY US 40011QALY China Benmelstobart plus anlotinib EC group likely costeffective US WTP threshold 150000QALY China current prices 80 price reduction China would necessary align WTP threshold emphasizing need policy intervention drug pricing reimbursement improve patient access",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40705178/",
        "source_type": "Global"
    },
    {
        "pmid": "40704030",
        "title": "Cost-utility and budget impact analyses of valganciclovir for cytomegalovirus retinitis in patients with human immunodeficiency virus in Thailand.",
        "abstract": "Cytomegalovirus retinitis CMVR opportunistic infection frequently seen people living HIV PLHIV cause blindness Intravenous IV ganciclovir typical CMVR treatment Thailand oral valganciclovir convenient alternative However costeffectiveness budget impact remain unclear Therefore study aimed analyse costutility budget impact oral valganciclovir compared IV ganciclovir CMVR treatment PLHIV Thailand hybrid decision treeMarkov model developed estimate costs qualityadjusted life year QALYs life year LYs Cost utility probability parameter obtained published literature national databases costutility analysis performed estimate incremental costeffectiveness ratios whereas budget impact analysis BIA performed assess financial implications Sensitivity analysis performed assess model uncertainty Oral valganciclovir dominant treatment providing higher QALYs 350 vs 323 LYs 478 vs 475 lower total cost 133630 THB vs 163024 THB IV ganciclovir Oneway sensitivity analysis revealed retinal detachment probability drug cost inpatient service cost influential parameters Probabilistic sensitivity analysis revealed 943 simulation placed oral valganciclovir dominant quadrant BIA revealed annual cost reduction 6408714 THB replacing IV ganciclovir oral valganciclovir Oral valganciclovir costeffective demonstrated budget reduction compared IV ganciclovir finding provide valuable insight enhancing CMVR management ensuring efficient healthcare resource allocation",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40704030/",
        "source_type": "Global"
    },
    {
        "pmid": "40701591",
        "title": "Assessing the quality of amoxicillin in the private market in Indonesia: a cross-sectional survey exploring product variety, market volume and price factors.",
        "abstract": "assess quality amoxicillin product Indonesias private market surveying range product available across different areas followed product sampling laboratory testing crosssectional survey employing mystery shopper purposively sample widest possible range amoxicillin product available patient across different area Indonesia Licensed unlicensed medicine outlet remote rural urban area online Amoxicillin product sold patient oral solid dry liquid formulations Quality amoxicillin products assessed using compendial testing active pharmaceutical ingredient content dissolution Samples failed quality test classified substandard outofspecification OOS raw prevalence substandard amoxicillin adjusted based national market volume product variant surveyed 476 outlets mostly pharmacy 685 website 197 drug store 109 Among 120 collected samples 59 distinct products collectively representing 95 estimated market volume oral solid product 65 dry syrups 12 110 oral solid sample tested OOS 109 3 10 dry syrup 30 sample failed originated various area type outlets found relation price quality amoxicillin oral solid amoxicillin product tested OOS represent estimated 127 national market volume found relation price quality amoxicillin Combining productvariety sampling data market volume present promising approach gain insight prevalence poorquality medical product using relatively small sample size",
        "mesh_terms": [
            "Indonesia",
            "Cross-Sectional Studies",
            "Amoxicillin",
            "Humans",
            "Anti-Bacterial Agents",
            "Private Sector",
            "Commerce",
            "Pharmacies",
            "Surveys and Questionnaires"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40701591/",
        "source_type": "Global"
    },
    {
        "pmid": "40699577",
        "title": "Difficulty With Binary Voting Among FDA Oncology Advisory Committee Members.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40699577/",
        "source_type": "Global"
    },
    {
        "pmid": "40693038",
        "title": "Spatiotemporal patterns and influencing factors of genotypic resistance testing utilization among people living with HIV: A 10-year retrospective analysis at a tertiary care hospital in Beijing, China (2014-2023).",
        "abstract": "Prior research indicated low genotypic resistance testing GRT human immunodeficiency virus HIV utilization China due partial cost coverage national antiretroviral therapy policies limited testing accessibility financial barriers Temporal spatial data GRT trend also scarce analyzed GRT pattern among 6895 untreated individual tertiary hospital using Joinpoint regression multivariable logistic modeling spatial analysis GeoDaSatScan GRT rate showed significant twophase upward trend increasing 536  2014 7417  2023 average annual percentage change 3130  iPi  0001 Beijing residency adjusted odds ratio aOR  2596 95  confidence interval CI 23072921 older age associated higher GRT uptake Specifically age 3544 year aOR  1207 95  CI 10261420 4554 year aOR  1335 95  CI 11041613 ≥ 55 year aOR  1424 95  CI 11261802 significantly higher odds testing Lower testing rate observed individual lower education attainment high school technical secondary aOR  0827 junior high school aOR  0835 primary school aOR  0695 unknown sexually transmitted disease STDs history aOR  0415 nonheterosexual transmission route homosexual aOR  0834 Spatial analysis identified GRT clustering across Beijing 2021 two spacetime cluster identified 20192023 20182022 study demonstrates substantial increase GRT uptake achieving balanced districtlevel distribution since 2021 Age educational attainment STDs history transmission route influence GRT utilization Improving access reducing costs implementing targeted intervention critical optimizing testing guiding antiretroviral therapy decisions",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40693038/",
        "source_type": "Global"
    },
    {
        "pmid": "40692815",
        "title": "Off-label policy through the lens of trazodone usage and spending in the United States.",
        "abstract": "Offlabel prescribingwhen medication used indication approved Food Drug Administrationis widespread US health care system study used trazodone drug approved 1981 depression case study examine broader issue surrounding offlabel utilization spending Although approved treat depression trazodone frequently prescribed offlabel indication uncertain clinical value insomnia anxiety Using nationally representative data Medical Expenditure Panel Survey estimated approximately 24 million trazodone prescription filled 2019 health care spending 294 million least 85 prescription ∼20 million 84 spending 247 million offlabel indications primarily insomnia Health plan reimbursement per prescription nearly identical onlabel offlabel use despite significant evidence gap finding illustrate scale inefficiency offlabel prescribing highlight challenge facing clinicians patients payers propose set policy solutionsincluding public private investment evidence generation pricing drug account offlabel use valuebased reimbursementto advance efficient system offlabel use Trazodone present revealing case broader systemic problem offlabel prescribing indication uncertain clinical value",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40692815/",
        "source_type": "Global"
    },
    {
        "pmid": "40690228",
        "title": "Managing Anticancer Drug Spending in Medicare.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40690228/",
        "source_type": "Global"
    },
    {
        "pmid": "40689371",
        "title": "Utilization and Determinants of Anticancer Drugs Under China's National Drug Price Negotiation Policy.",
        "abstract": "Chinese government began take national drug price negotiation NDPN 2016 aiming enhance accessibility affordability anticancer drugs study aim assess utilization influence factor anticancer drug NDPN policy China Gastric cancer patient within chemotherapy included Independent variable measured age gender insurance type total medical expenditure THE length stay LOS drugtototalexpense ratio DTR primary outcome negotiated drug usage cost treatment outcome Twopart model used identify influence factor anticancer drug utilization Propensity Score Matching PSM employed evaluate impact negotiated drug utilization treatment outcome among inpatients sample included 9868 gastric cancer patient three cities Outpatient patient demonstrated limited utilization negotiated drug 133 Patients aged 6175 β0923 P  001 75 year β0946 P  005 likely use negotiated drugs Key factor influencing inpatient drug utilization included medical insurance type β0245 P001 LOS β0122 P0001 DTR 0037 P0001 use negotiated drug significant effect treatment outcomes limited utilization negotiated drug outpatient arises urgent necessity comprehensive insurance coverage significant outcome effect dedicated importance rigorously validate effectiveness drug abundant realworld evidence foreseeable future",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40689371/",
        "source_type": "Global"
    },
    {
        "pmid": "40689243",
        "title": "Examining Pricing and Availability for Neglected Tropical Disease Therapies in the United States.",
        "abstract": "Neglected tropical disease primarily affect vulnerable population lowresource setting worldwide United States neglected tropical disease Chagas soiltransmitted helminthiases infection historically affected immigrant increasingly relevant US resident climate change examined pricing prescribing rates supply therapy used treat neglected tropical disease United States implication accessibility patient care retrospective analysis prescription rates wholesale acquisition costs shortage conducted 11 treatment product 2019 2024 aggregating data Symphony Metys First Databank NAVLIN Red Book University Utah Drug Information Service price neglected tropical disease stable albendazole price decreased 78 mebendazole price rose 60 Miltefosine remained expensive 48 000 per treatment course limited manufacturer neglected tropical disease treatment United States increasing vulnerability shortages Addressing pricing irregularity supply vulnerability requires legislative policy intervention enhance generic competition expand public manufacturing strengthen supply chains measure critical ensuring affordable accessible treatment option neglected tropical disease United States",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40689243/",
        "source_type": "Global"
    },
    {
        "pmid": "40686673",
        "title": "Impact of COVID-19 on disease-specific mortality, healthcare resource utilization, and disease burden across a population over 1 billion in 31 countries: an interrupted time-series analysis.",
        "abstract": "COVID19 pandemic disrupted global health affected chronic disease management study quantified impact pandemic diseasespecific measure health dynamics mortality rates healthcare resource utilization HRU disease burden interrupted timeseries analysis performed examining temporal trend across disease category two periods prepandemic pandemic after January 2020 Monthly mortality data collected 31 countries monthly HRU disease burden data collected South Korea defined primary outcome diseasespecific mortality rate number patients outpatient visits day hospitalization disease burden per caput cost used generalized least square model AR 1 residual automated SARIMA model BenjaminiHochbergadjusted qvalues applied statistical significance q  005 significant increase diseasespecific mortality observed across multiple countries circulatory disease showing widespread rise HRU declined across disease categories including reduction patient numbers outpatient visits hospital stays however patient number showed sustained increase neoplasm mental disorder Although change total direct medical cost varied disease per caput cost initially increased despite decrease number patients pandemic led increased mortality disease burden limited access healthcare services Establishing resilient healthcare system appropriate public health policy key ensure continuity care national crises Ministry Food Drug Safety Korea National Research Foundation Korea Korean Government Korea Environment Industry  Technology Institute",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40686673/",
        "source_type": "Global"
    },
    {
        "pmid": "40686094",
        "title": "A cost-effectiveness analysis of behavioural, pharmacological, and surgical obesity treatments in Canada.",
        "abstract": "Effective weight management pharmacotherapies new alternative bariatric surgery health behaviour intervention HBI alone Comparative costeffectiveness evaluation guide decisionmaking aimed evaluate costeffectiveness sleeve gastrectomy SG RouxenY gastric bypass RYGB semaglutide tirzepatide HBI compared treatment preventing cardiometabolic complication among Canadian adult class III obesity developed cohortbased Markov model 40year time horizon examined cardiometabolic complication 40yearolds class III obesity BMI ≥40 kgmsup2sup without type 2 diabetes cardiovascular disease baseline compared SG RYGB semaglutide 24 mg tirzepatide 15 mg HBI treatment obtained data treatment effects probabilities utilities cost published literature expressed effectiveness qualityadjusted life year QALYs estimated cost Canadian public payer perspective Outcomes included incremental costeffectiveness ratio ICERs evaluated CAD 50 000QALY willingnesstopay threshold RYGB HBI costeffective strategies HBI costeffective versus treatment ICER 14 279QALY RYGB demonstrated highest QALYs 2020 costeffective strategy versus tirzepatide ICER 44 667QALY Semaglutide SG strongly dominated due higher cost lower effectiveness Tirzepatide extendedly dominated RYGB Sensitivity analysis confirmed finding showed lower drug price could improve pharmacotherapy costeffectiveness RYGB HBI costeffective managing class III obesity RYGB provided greatest health gains access remains limited Neither pharmacotherapy costeffective current prices Lower drug price could significantly improve pharmacotherapy costeffectiveness",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40686094/",
        "source_type": "Global"
    },
    {
        "pmid": "40684026",
        "title": "Cost-Effectiveness Analysis of Toripalimab Plus Axitinib for Patients with Advanced Renal Cell Carcinoma in the United States.",
        "abstract": "RENOTORCH trial found toripalimab plus axitinib extended progressionfree overall survival patient advanced renal cell carcinoma RCC though financial burden may limit widespread use study aimed assess costeffectiveness toripalimab plus axitinib compared sunitinib monotherapy firstline therapy patient previously untreated intermediate poorrisk advanced RCC US thirdparty payer perspective threestate partitioned survival model progressionfree progression death utilized clinical outcome obtained RENOTORCH trial Progressionfree survival PFS overall survival OS modeled using various parametric function 5year horizon applying 3 annual discount rate Costs treatments administration monitoring management grade 34 adverse event ≥ 5 occurrence sourced Micromedex® Centers Medicare  Medicaid Services CMS databases Life year LY qualityadjusted life year QALY incremental cost per LY QALY estimated Oneway probabilistic sensitivity analysis conducted Subgroup analysis intermediate poorrisk patients classified International Metastatic RCC Database Consortium IMDC criteria performed using similar methods Toripalimab plus axitinib increased total cost 332359 gained 068 LY 036 QALY compared sunitinib resulting incremental cost 489747 per LY 923962 per QALY Oneway sensitivity analysis showed incremental cost per QALY sensitive change toripalimab plus axitinibs cost 150000 willingnesstopay threshold probabilistic sensitivity analysis showed nearly 0 probability toripalimab plus axitinib costeffective Similarly toripalimab plus axitinib still costeffective intermediate poorrisk patients Compared sunitinib monotherapy study suggested toripalimab plus axitinib costeffective patient advanced renal cell carcinoma US thirdparty payer perspective analysis warranted data available Despite benefit across different risk groups toripalimab plus axitinib costeffective intermediate poorrisk patients",
        "mesh_terms": [
            "Humans",
            "Axitinib",
            "Carcinoma, Renal Cell",
            "Cost-Benefit Analysis",
            "Kidney Neoplasms",
            "United States",
            "Antibodies, Monoclonal, Humanized",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Quality-Adjusted Life Years",
            "Sunitinib",
            "Cost-Effectiveness Analysis"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40684026/",
        "source_type": "Global"
    },
    {
        "pmid": "40683012",
        "title": "Exposure to cannabis marketing in the United States and differences by cannabis laws: Findings from the International Cannabis Policy Study.",
        "abstract": "growing number US state legalized adult recreational cannabis however little evidence impact cannabis policy cannabis marketing exposure date current study examined marketing exposure US including difference state cannabis illegal illegal states legal medical use medical legal recreational use recreational Data US component International Cannabis Policy Study national repeat crosssectional data survey conducted 187573 respondent aged 1665 6 annual survey wave 20182023 Adjusted mixed effect logistic regression GLIMMIX model examined difference selfreported exposure cannabis marketing noticing statelevel cannabis laws Selfreported exposure cannabis marketing differed across policy changes Noticing cannabis marketing lowest illegal state increased first 12months following medical legalization 354  vs 392  AOR116 95  CI101133 p  0034 Noticing marketing highest recreational states increase first 12months following legalization 500  vs 411  AOR141 95  CI134148 p  001 additional increase 13 year 562  AOR120 95  CI114125 p  001 4 year following legalization 639  AOR121 95  CI116127 p  001 Noticing highest among people consume cannabis younger ages Selfreported exposure cannabis marketing increase following medical recreational legalization disproportionately noticed underaged people Cannabis regulation legal market account marketing shown promote cannabis use",
        "mesh_terms": [
            "Humans",
            "United States",
            "Adult",
            "Middle Aged",
            "Adolescent",
            "Male",
            "Female",
            "Young Adult",
            "Marketing",
            "Cannabis",
            "Cross-Sectional Studies",
            "Aged",
            "Legislation, Drug",
            "Marijuana Use"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40683012/",
        "source_type": "Global"
    },
    {
        "pmid": "40678407",
        "title": "Comparative Cost Analysis for Direct Medical Costs of Protocol Administration of Non-Small Cell Lung Cancer Treatment Regimens in Curative Intent: A Micro-Costing Study in Jordan.",
        "abstract": "Nonsmall cell lung cancer NSCLC treatment cost significantly impact healthcare systems study analyzes direct cost cost driver perioperative adjuvant systemic treatment stage III NSCLC Jordanian healthcare providers perspective using microcosting methodology employed microcosting analyze direct medical expense including drug acquisition preparation administration prepostmedications diagnostics labor wastage cost perioperative regimen used stage III NSCLC International guideline defined therapeutic regimens drug price extracted Jordan Food Drug Administrations database Published data survey quantified microcosts Among 26 assessed regimen 2 targeted therapy 10 chemotherapy 10 chemoimmunotherapy 4 immunotherapy targetedimmunotherapy agent significantly increased costs Chemotherapy regimen cost difference ranged 63368 squamous 176391 nonsquamous per cycle Antineoplastic agent primary cost drivers highest Durvalumab 9872 cycle cost Laboratory cost comprised 5073 chemotherapy 724 immunotherapy regimens Wastage contributed 1036 total cycle costs Average administration cost 35 per cycle Maximum cycle cost were targeted therapy Osimertinib 720644 immunotherapy Durvalumab 905771 immunechemotherapy DurvalumabCarboplatinPemetrexed 1135843 chemotherapy CarboplatinPemetrexed 230072 result highlight substantial economic impact cost variability among treatment regimens variability present opportunity cost reduction careful selection therapeutically equivalent regimen based pricing toxicity profiles finding emphasize need comprehensive precise cost analysis inform healthcare policy clinical practices Future research focus costeffectiveness analysis expensive agent ensure value money support evidencebased decisionmaking strengthen price negotiation suppliers",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40678407/",
        "source_type": "Global"
    },
    {
        "pmid": "40674723",
        "title": "China's online pharmacy: its regulatory policy and a future research agenda for the emerging AI age.",
        "abstract": "recent years China witnessed remarkable digital health movement wherein online pharmacy drug ecommerce emerged disruptive business models 2019 China amended Drug Administration Law permit online sale prescription drug customers albeit certain limitations marked Chinas first national congresslevel regulatory policy online pharmacy regulation policy comprises two subpolicies one targeting thirdparty online platform involved drug sale another aimed controlled drug drug special administration prohibited sold online However regulatory policy sparked legal ethical debates first revolves around whether online platform engaged drug sale enjoy liability protection extent second center ethical dilemma concerning access controlled drug due blanket ban online sales article thoroughly examines aforementioned regulatory policy Moreover coronavirus disease2019 COVID19 pandemic surge artificial intelligence AI application within Chinas healthcare sector leading phenomenal growth AIdriven online pharmacy staffed socalled AI doctor pharmacists article outline future research agenda regulating emerging AIenabled online pharmacy postpandemic age concluding",
        "mesh_terms": [
            "China",
            "Humans",
            "COVID-19",
            "Artificial Intelligence",
            "Pharmaceutical Services, Online",
            "SARS-CoV-2",
            "Drug and Narcotic Control"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40674723/",
        "source_type": "Global"
    },
    {
        "pmid": "40672914",
        "title": "Will centralized drug procurement policy improve enterprises' total factor productivity?",
        "abstract": "backdrop Chinas healthcare reform challenge drug pricing study investigates impact National Centralized Drug Procurement NCDP policy implemented 2018 Employing DifferenceinDifferences DID methodology quarterly data Ashare listed pharmaceutical firm 20032021 sourced WINDCSMAR databases demonstrate NCDP participation significantly reduces Total Factor Productivity  Robustness confirmed index substitution propensity score matching lag tests negative effect amplified nonstateowned enterprises nonTCM manufacturers firm high analyst coverage Mechanistically NCDP suppresses TFP through i tightened financing constraint ↑KZ index impairing capital allocation efficiency ii indirect pathway shortterm RD surge ↑RD trigger resource crowdingout effects compounded diminished investment efficiency ↑INV ultimately forming RD→investment inefficiency→TFP↓ transmission chain reconcile public welfare objective corporate sustainability propose dual optimization strategies idifferentiated financing supporti iinnovation incentive reformi establish sustainable equilibrium price control TFP enhancement providing actionable solution nationwide NCDP scaling",
        "mesh_terms": [
            "Humans",
            "China",
            "Drug Industry",
            "Efficiency, Organizational",
            "Health Policy",
            "Drug Costs"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40672914/",
        "source_type": "Global"
    },
    {
        "pmid": "40671596",
        "title": "Affordability issues and the need for a reimbursement process of advanced therapy for inflammatory bowel diseases in India.",
        "abstract": "Inflammatory bowel disease IBD aggressive relapsing condition develop young age carry high lifetime risk medical expenses Patients moderatetosevere Crohns disease Ulcerative colitis need biologic therapy induction maintenance remission cost treating moved hospitalization surgery biologics partly reimbursed review identifies handful insurance company provide daycare coverage biologic infusion injection get reimbursed 24hour admission India varies patient patient one insurance company another biosimilars antiTNFs drive saving overall costs Patients made accept substantial cost deductibles copayments coinsurance insurance partially cover financial risk healthcare IBD remains affordable some manufacturer need comprehend payers perspective deliver best possible patient outcomes pricing strategy indicationspecificvolumebased pricing Small molecule adoption potential disrupt infusionbased reimbursement policy shifting care pharmacybased models improving access rural populations need implement universal health coverage post mortgage model used spread cost biologics time IBD payers perspective must considered determining cost product include patient healthcare policy decisionmaking",
        "mesh_terms": [
            "Humans",
            "India",
            "Inflammatory Bowel Diseases",
            "Insurance, Health, Reimbursement",
            "Reimbursement Mechanisms"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40671596/",
        "source_type": "Global"
    },
    {
        "pmid": "40669769",
        "title": "Medicare Drug Price Negotiation Under The Inflation Reduction Act: Ensuring the Continuity of Critical Real-world Pharmaceutical Studies.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40669769/",
        "source_type": "Global"
    },
    {
        "pmid": "40668561",
        "title": "Quantifying the Role of Specialty Medications in Medicare Part D Expenditures in Dermatology.",
        "abstract": "rising cost prescription drug major concern health care Specialty medications particularly biologics transformed dermatologic care expensive may factor disproportionate growth spending assess role specialty medication Medicare Part drug spending among physician dermatologist dermatologyfocused advanced practice clinician nurse practitioner physician assistants 2013 2022 economic analysis used Medicare Part prescriber data drug prescription 2013 2022 report prescription drug claim physician dermatologist dermatologyfocused advanced practice clinicians identified using validated administrative claimsbased definitions Data analyzed December 17 2024 May 31 2025 Prescription volumes average prices introduction new drugs primary outcome growth inflationadjusted total dermatology drug spending decomposed specialty status prescriptions prices US Food Drug Administration approval year assessed Centers Medicare Medicaid Services Part prescriber data 2013 2022 94 900 359 drug claim 24 731 dermatology care professionals inflationadjusted Medicare Part spending increased 161 annually 768 million 2013 295 billion 2022 Specialty medication contributed 984 growth increasing 308 dermatology drug spending 2013 809 2022 despite 29 prescriptions Average inflationadjusted price per 30day prescription specialty medication increased 51 per year 3738 2013 5872 2022 contrast price nonspecialty medication decreased 53 annually relative inflation 68 2013 42 2022 growth specialty medication spending due increased prescribing 805 rather higher price 195 New therapy approved 2013 Otezla Cosentyx Taltz Dupixent Tremfya Skyrizi Odomzo accounted 695 spending growth Prescription rate increased slowly older specialty drug Humira Enbrel Stelara Erivedge price increased 92 annually price newer agents Results economic evaluation suggest specialty medication become substantial factor dermatology drug spending price average dermatologic medication increased rapidly primarily reflects increased prescribing newly introduced specialty drugs therapy expand treatment options rising share cost highlight need policy balance innovation access affordability",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40668561/",
        "source_type": "Global"
    },
    {
        "pmid": "40660747",
        "title": "Cost and clinical flow of point-of-care urine tenofovir testing for treatment monitoring among people living with HIV initiating ART in South Africa.",
        "abstract": "Pointofcare POC urine tenofovir TFV test provide timely information regarding antiretroviral therapy ART adherence support management HIV treatment clinics However limited data cost feasibility integrating POC testing HIV clinic subSaharan Africa characterized clinic flow implementation cost POC adherence testing person initiating ART HIV care clinic South Africa conducted microcosting within randomized controlled implementation trial POC TFV test government clinic Durban South Africa STREAM HIV Timeandmotion observation conducted 1st March 31st December 2022 assess staff client time needed POC TFV testing counselling estimated financial economic cost capital clinic consumables personnel using provider national government perspective estimated cost POC TFV USD 13 per client assuming clinic volume 20 individual initiating ART per month largest component cost POC TFV testing test strip consumables accounted 53 test cost median total time clinic visit POC TFV test starting client registration 4919 minutes seconds IQR 29198935 TFV testing took 922 IQR 7351411 taking 19 total clinic visit time including sample collection sample loading TFV test processing counselling provision based test results Overall 29 clinic visit time included direct clinical care assessment provider client spending median 1409 IQR 10352122 getting vitals checked receiving adherence monitoring via POC TFV testing collecting ART refill Waiting line ART took 48 clinic visit time POC TFV testing administered reasonable costs requires less 10 minute healthcare provider time and therefore may feasible implement South African clinics Findings inform policy budgetary planning ART monitoring South Africa future costeffectiveness analysis POC TFV testing NCT04341779",
        "mesh_terms": [
            "Humans",
            "HIV Infections",
            "Tenofovir",
            "South Africa",
            "Anti-HIV Agents",
            "Point-of-Care Testing",
            "Male",
            "Female",
            "Point-of-Care Systems",
            "Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40660747/",
        "source_type": "Global"
    },
    {
        "pmid": "40659975",
        "title": "Revenue, Patents, and New Generic Competition for Prescription Drugs in the USA.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40659975/",
        "source_type": "Global"
    },
    {
        "pmid": "40653930",
        "title": "Share of Sales Subject to Medicare Inflation Rebates and Price Increases of Top-Selling Drugs.",
        "abstract": "examine whether new Medicare inflation rebate policy associated change manufacturer pricing behavior crosssectional study 156 topselling brandname drugs used linear regression evaluate whether association drugs exposure policy ie Medicares share net US sales difference yearoveryear price change 20212022 versus 20222023 20232024 policy took effect study used Medicare spending data average sale price Centers Medicare Medicaid Services wholesale acquisition cost Eversana NAVLINs Price  Access database sale revenue estimated rebate SSR Health Vaccines biosimilars drug approved 2020 generic biosimilar competition 2023 excluded Drugs stratified whether derived sale Medicare Part B Part D median Medicare share net sale 28 IQR 1837 50 Part B drug 32 IQR 1649 106 Part drugs Median yearoveryear price change 20212022 20222023 20232024 32 29 34 Part B drug 50 59 49 Part drugs association drugs Medicare share net sale difference price change pre vs postpolicy Part B drug 2023 p  099 2024 p  009 Part drugs 10 increase drugs share Medicare sale associated 018 95 CI 001035 p  004 higher price change first year policy implementation significant association second year p  017 Medicare inflation rebate associated smaller price increase among topselling drug affected policy Additional measure needed prevent drug manufacturer raising price year extending inflation rebate commercially insured patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40653930/",
        "source_type": "Global"
    },
    {
        "pmid": "40652608",
        "title": "Associations between local cigarette and e-cigarette prices and smoke-free legislation with prenatal smoking and birth outcomes.",
        "abstract": "state cigarette tax shown reduce disparity prenatal smoking birth outcomes less known effect local tobacco control policies examined association countylevel cigarette ecigarette price smokefree legislation racialethnic educational disparity prenatal smoking birth outcomes Using 20132018 countylevel natality data 18663683 singleton linked cigarette ecigarette price data smokefree legislation conducted conditional mixedprocess model examine association tobacco control policy prenatal smoking associated change birth outcomes included interaction raceethnicity education prices Cigarette price increase associated larger decline prenatal smoking ecigarette prices effect size decreasing across educational gradient Among woman 011 year education 10  increase cigarette price associated decrease smoking 861 percentage point White woman 292 percentage point Black woman subsequently increase infants birth weight 801 272 g respectively Increases cigarette ecigarette smokefree legislation coverage associated small decline prenatal smoking subsequent change birth outcomes Local cigarette price increase contribute flattening educational gradient prenatal smoking birth outcomes particularly among White Black women Local cigarette price may indicative fiscal policy influence smoking behavior state cigarette taxes particularly loweducated pregnant woman likely price sensitive",
        "mesh_terms": [
            "Humans",
            "Female",
            "Pregnancy",
            "Adult",
            "Tobacco Products",
            "Smoke-Free Policy",
            "Electronic Nicotine Delivery Systems",
            "Pregnancy Outcome",
            "Commerce",
            "Smoking",
            "Young Adult",
            "Birth Weight",
            "Taxes",
            "Infant, Newborn",
            "Adolescent"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40652608/",
        "source_type": "Global"
    },
    {
        "pmid": "40646427",
        "title": "Public perceptions of high-cost cancer drugs and the implications for reimbursement decisions.",
        "abstract": "Reimbursing highcost cancer drug present challenge managing uncertainty setting appropriate prices controlling pharmaceutical expenditures examined perspective South Korean public highcost cancer drug policy option improve reimbursement treatments conducted selfrated webbased survey November December 2023 used quota sampling method based South Korean census data recruit study participants questionnaire comprised four sections sociodemographics definition highcost cancer drug reason reimbursement uncertainty associated highcost cancer drugs policy option improve reimbursement treatments 11974 invitation sent 1000 participant completed survey resulting response rate 835 Threequarters respondent agreed strongly agreed highcost cancer drug reimbursed 70 accepted need price negotiations even lead drug withdrawal delay reimbursement decisions similar proportion agreed new policy options dual pricing additional funding introduced caution South Korean public perceives reimbursement highcost cancer drug human right measure government responsibility However support reimbursement confident drug safe effective costeffective",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40646427/",
        "source_type": "Global"
    },
    {
        "pmid": "40644379",
        "title": "Tenofovir alafenamide is superior to tenofovir disoproxil fumarate and entecavir in cost-effectiveness of treatment of chronic hepatitis B in china with new volume-based procurement policy.",
        "abstract": "Evidence support longterm efficacy Nucleostide Analogs NAs therapy improving chronic hepatitis B CHB prognosis However determining costeffective firstline NAs remains unclear Chinas implementation New VolumeBased Procurement Policy NVBP Policy 2019 led substantial price reduction entecavir ETV tenofovir disoproxil fumarate TDF tenofovir alafenamide TAF study assesses costeffectiveness ETV TDF TAF without NVBP CHB China statetransition model parameterized using data published literature utilized compare treatment strategy encompassing nonNAs best support care BSC ETV TDF TAF without NVBP simulated lifetime cohort employed measuring outcome predicted liverrelated deaths costs qualityadjusted lifeyears QALYs incremental costeffectiveness ratio ICERs comparison NonNAs BSC TAF yielded additional 268 QALYs per person ICER 785322 USDQALY Subsequently TDF generated additional 261 QALYsperson ICER 715339 USDQALY ETV produced additional 201 QALYsperson ICER 936674 USDQALY without NVBP Incorporating NVBP ICERs TAF TDF ETV decreased 74562 USDQALY 72933 USDQALY 87111 USDQALY respectively compared nonNAs BSC willingnesstopay WTP threshold ranging 12500 USDQALY 37500 USDQALY TAF NVBP showed increased probability 51155247 optimal treatment strategy followed TDF ETV NVBP exhibiting reduced likelihood 43094245 640448 iterations analysis suggests TAF NVBP represents costeffective longterm therapy CHB TDF ETV without NVBP TAF without NVBP considered costineffective",
        "mesh_terms": [
            "Humans",
            "Hepatitis B, Chronic",
            "Tenofovir",
            "Guanine",
            "Cost-Benefit Analysis",
            "China",
            "Adenine",
            "Antiviral Agents",
            "Quality-Adjusted Life Years",
            "Alanine",
            "Male",
            "Female"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40644379/",
        "source_type": "Global"
    },
    {
        "pmid": "40643355",
        "title": "Historical and contextual variation in daily opioid consumption rates: implications for supply control, service delivery, and research.",
        "abstract": "iBackgroundi Illegal opioids create substantial harms extent depends multiple factors including amount consumediObjectivesi examine consumption varies across time context implication treatment drug policyiMethodsi searched EBSCOhost PubMed literature individuals 1 notintreatment purchasing illegal markets 2 reporting pretreatment use treatment intake 3 opioid use disorder OUD receiving medically supplied opioids total 135 article deemed relevantiResultsi Average consumption intensity vary enormously 100 morphine milligram equivalent MME per day use outside treatment price high 600 MME typical illegal markets 11001800 MME per day supply free heroin assisted treatment injectable hydromorphone treatment MME methadone program 190460 less traditional British heroin prescribing system 6001300 Intensities tended higher recent times whereas price lower Studies fentanyl era suggest MMEs per day may much higher pastiConclusioni adaptability consumption several potential implications Expansions supply could greater effect quantity consumed prevalence Treatment protocol overdose prevention strategy may need adjust higher baseline consumption Furthermore assumption health harm longterm use may need revisiting predicated lower historical consumption intensities finding caveated limitation reporting data variation methodologies Hence greater investment monitoring consumption intensity warranted",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40643355/",
        "source_type": "Global"
    },
    {
        "pmid": "40634893",
        "title": "Does Global Budget promote the construction of integrated healthcare delivery system? Evidence from Sanming, China.",
        "abstract": "Chinese government advancing development County Medical Community CMC establish integrated healthcare delivery network ensure health equity Recently Global Budget GB economic incentive implemented CMC Although impact GB medical expenditure demonstrated little evidence whether GB promotes collaboration among various providers article take Sanming City typical example Chinas healthcare reform case study us data 2016 2023 operation CMC Interrupted time series analysis used evaluate longterm impact GB inpatient costs cost structure service delivery analysis indicate that although direct impact GB inpatient cost significant sustains rational structure inpatient cost optimizes delivery inpatient service level institutions respect inpatient cost structure proportion drug cost secondary hospital SHs βsub3sub  0127 P  0001 tertiary hospital THs βsub3sub  0120 P  005 increased GB proportion testing inspection cost primary healthcare institution PHIs decreased βsub3sub  0215 P  005 term service delivery average length stay SHs βsub3sub  0053 P  005 THs βsub3sub  0032 P  0001 decreased admission per 100 outpatient βsub3sub  0058 P  0001 PHIs increased robustness analysis corroborated robustness results article provides empirical evidence GB mechanism enhance service coordination among different level healthcare providers provides valuable lesson promoting integrated healthcare achieving health equity China low middleincome countries",
        "mesh_terms": [
            "China",
            "Humans",
            "Budgets",
            "Delivery of Health Care, Integrated",
            "Health Care Reform",
            "Interrupted Time Series Analysis",
            "Organizational Case Studies"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40634893/",
        "source_type": "Global"
    },
    {
        "pmid": "40633905",
        "title": "Budget impact analysis of treatment-free remission in chronic myeloid leukemia patients treated with nilotinib in Tunisia.",
        "abstract": "emergence treatmentfree remission mark significant shift clinical management chronic myeloid leukemia patients involves discontinuation tyrosine kinase inhibitor therapy maintaining sustained molecular response light this study aim evaluate budget impact associated healthcare strategy among tunisian patient treated nilotinib economic evaluation seek provide insight affordability implementing treatmentfree remission perspective Tunisian National Health Insurance Fund threeyear time horizon Markov model assessed introduction treatmentfree remission eligible population input data used transition probability identification target population obtained systematic literature review economic evaluation considered drug acquisition cost direct cost covered public payer account variability results oneway deterministic sensitivity analysis conducted varying key model parameters initial cohort 32 eligible patient within health insurance database model estimated evolution target population 230 patient three years introduction treatmentfree remission new strategy management chronic myeloid leukemia would result costsaving estimated 234 million Tunisian Dinars uncertainty analysis revealed significant impact drug price overall outcomes study provides transparent interpretable result decisionmakers economic evaluation reveals financial gain allocated address health priority within Tunisian National Health Insurance Funds budget budget impact analysis advocate implementing treatmentfree remission costsaving intervention Tunisian National Health Insurance Funds budget",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40633905/",
        "source_type": "Global"
    },
    {
        "pmid": "40632461",
        "title": "Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors.",
        "abstract": "Pembrolizumab show effectiveness treating metastatic nonsmall cell lung cancer metNSCLC subgroup patient experiencing longterm survival LTS benefits existence LTS subgroup may influence costeffectiveness pembrolizumab monotherapy compared platinumbased chemotherapy study aim assess potential implication subgroup costeffectiveness patient nonsquamous metNSCLC PDL1 ≥ 50 ineligible targeted therapies study used decision analytic model based Dutch realworld data 20082014 Two strategy simulated 1 chemotherapy strategy patient receive chemotherapy first second thirdline 2 pembrolizumab strategy patient receive firstline pembrolizumab followed chemotherapy progressing second thirdlines pembrolizumab strategy evaluated without assumption LTS subgroup LTS subgroup assumed free metNSCLCrelated progression treatment Costs 2022 € including drug costs direct medical costs family costs healthcare cost life year gained considered firstline treatment death Effects measured qualityadjusted life year QALYs incremental costeffectiveness ratio ICER assessed using €80000QALY threshold Threshold analysis performed size mortality rate LTS subgroup price pembrolizumab QALYs per patient 065 chemotherapy 124 pembrolizumab without LTS 352 pembrolizumab LTS Average cost per patient €58800 chemotherapy €154600 pembrolizumab without LTS €178600 pembrolizumab LTS Pembrolizumab without LTS costeffective compared chemotherapy ICER €167600QALY pembrolizumab LTS 30 simulated population cost effective ICER €43100QALY Threshold analysis showed LTS subgroup size least 10 halving price pembrolizumab needed pembrolizumab costeffective Pembrolizumab costeffective firstline treatment patient metNSCLC PDL1 ≥ 50 Netherlands least 10 patient longterm survivors Without longterm survivors treatment costeffective Therefore crucial consider longterm survivor assessing costeffectiveness immunotherapy metNSCLC",
        "mesh_terms": [
            "Humans",
            "Antibodies, Monoclonal, Humanized",
            "Cost-Benefit Analysis",
            "Carcinoma, Non-Small-Cell Lung",
            "Lung Neoplasms",
            "B7-H1 Antigen",
            "Antineoplastic Agents, Immunological",
            "Quality-Adjusted Life Years",
            "Male",
            "Netherlands",
            "Female"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40632461/",
        "source_type": "Global"
    },
    {
        "pmid": "40624840",
        "title": "Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies.",
        "abstract": "Therapeutic monoclonal antibody mAbs often designed bind target via antigenbinding domain Fabs also engage cell surface receptors FcγRs FcRn Fc regions may result variety functional outcomes including antibody dependent cellular cytotoxicity ADCC antibodydependent cellular phagocytosis ADCP complementdependent cytotoxicity CDC alteration circulating halflives Engineering Fc region achieve desirable pharmacology pharmacokinetics widely adopted strategy drug development Fc region modified amino acid substitution glycoengineering resulting enhanced reduced effector functions preferential binding FcR subtypes pHdependent binding FcRns alteration binding effector activity mAbs may potentially also accompanied undesirable effect safety concerns Critical assessment pharmacology safety nonclinical setting essential exposing human engineered mAb Fcmodified mAbs choice vitro vivo nonclinical pharmacology safety model need account specie difference FcR expression function potentially divergent effect Fc modification human versus nonclinical species impact target cognate ligand expression patterns potential impact emergent antidrug antibody directed mAb Using variety industry case studies highlight key aspect nonclinical pharmacology toxicology testing strategies factor influence choice nonclinical models translatability findings input health authority suggest best practice approach nonclinical testing Fc modified mAbs",
        "mesh_terms": [
            "Humans",
            "Protein Engineering",
            "Antibodies, Monoclonal",
            "Animals",
            "Immunoglobulin Fc Fragments",
            "Receptors, Fc",
            "Antibody-Dependent Cell Cytotoxicity",
            "Translational Research, Biomedical",
            "Drug Development",
            "Drug Industry"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40624840/",
        "source_type": "Global"
    },
    {
        "pmid": "40623875",
        "title": "Interventions to mitigate drug shortages in public health systems in sub-Saharan Africa: a scoping review protocol.",
        "abstract": "Globally drug shortage affect low middle highincome country different degrees challenge associated drug shortage health systems particularly public health facilities consequent multiple adverse effect patient health system led country continue explore implement different strategy combat challenge Various factor implicated drug shortage range manufacturing concerns demand issues supply chain disruption regulatory issues effect drug shortage health system range poor patient compliance therapeutic failure antimicrobial resistance low morale among healthcare worker public distrust government services Furthermore effect drug shortage public health facility include unavailability drug patients hospitalisation readmissions associated cost could avoided high outofpocket expenditure suffered patient patient resort buying drug private pharmacy price usually exorbitant prohibitive putting patient risk treatment default due lack affordability Successful mitigation strategy deployed prevent manage drug shortage subSaharan Africa SSA remain unshared despite potential strategy serve valuable lesson evidence scientifically synthesised reported scoping review synthesise evidence provide policy guidance better planning health service resources resulting improved quality life citizens underscoring importance functional responsive health systems Using Joanna Briggs Institute JBI scoping review methodology fivestage review outlined 1 determining research question 2 search strategy 3 inclusion criteria 4 data extraction 5 analysis presentation results literature search use PubMed SCOPUS Elsevier Science Direct search interfaces reflecting empirical grey literature focus literature published 2000 2025 study start end date 1 September30 November 2025 twostage screening process used determine eligibility articles article individually assessed eligibility two reviewers third reviewer resolve disagreements data eligible article extracted charted using standardised form Extracted data analysed using narrative descriptive analyses Ethical approval required scoping review use previously published data require human participation result search disseminated academic presentation conference peerreviewed publications",
        "mesh_terms": [
            "Humans",
            "Africa South of the Sahara",
            "Scoping Review as Topic",
            "Pharmaceutical Preparations",
            "Public Health",
            "Delivery of Health Care"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40623875/",
        "source_type": "Global"
    },
    {
        "pmid": "40621761",
        "title": "The Pharmacoeconomics and its Evaluation in Enhancing the Indian Healthcare System.",
        "abstract": "Escalating healthcare cost increasing demand healthcare system increased need efficient resource allocation Pharmacoeconomics vital field quantifies compare value therapeutic drug treatments provides systematic framework decisionmakers pharmaceutical industry government private sector optimize healthcare delivery spending review aimed explore role pharmacoeconomic model assessing economic clinical value therapies emphasizes importance costeffectiveness costutility costbenefit costminimization analysis balancing cost outcome guiding healthcare resource allocation Pharmacoeconomic methodology involve evaluating costs processes outcome associated therapeutic interventions Key method include costminimization costeffectiveness costutility costbenefit analyses approach critical regulatory compliance reimbursement decisions cost assessments sustaining pharmaceutical models review reveals pharmacoeconomic tool CostEffectiveness Analysis CEA CostUtility Analysis CUA CostBenefit Analysis CBA widely used guide healthcare policy decisions particularly resourceconstrained settings CEA commonly applied method due simplicity CUA gaining traction advanced policy framework like Health Technology Assessment HTA India pharmacoeconomic research emerging face barrier limited access realworld data absence national reimbursement systems high outofpocket costs Innovative method like machine learning pharmacogenomics explored improve relevance precision evaluations pharmacoeconomic model offer valuable insight healthcare decisionmaking realworld impact limited inconsistency data quality variation implementation standards India fragmented governance low public health spending lack coordination among stakeholder hinder effective application Addressing systemic challengessuch establishing interoperable data systems standard treatment guidelines equitable healthcare accessis crucial Tailored approaches including localized utility value digital health initiatives essential make pharmacoeconomics practical influential tool policy formulation resource allocation India similar settings Pharmacoeconomic study evaluate clinical efficacy adverse effects production cost incorporating perspective patients providers payers communities India unique challenge limited rural healthcare access infrastructure disparities high outofpocket expense necessitate tailored adaptations Strategies integrating accessibility metrics localized data equity considerations preventive care tiered pricing publicprivate partnership enhance healthcare delivery Pharmacoeconomic model essential improving health outcomes ensuring equitable resource allocation addressing diverse need India",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40621761/",
        "source_type": "Global"
    },
    {
        "pmid": "40618906",
        "title": "Relationship between an adult-use Cannabis law and Cannabis use by type in a cohort of New Jersey young adults.",
        "abstract": "Limited research evaluated impact cannabis policy young adult cannabis use full implementation retail outlet opened cannabis product type study examined relationship adultuse cannabis retail sale New Jersey United States young adult cannabis use type Data New Jersey young adult 1823 years Policy Communication Evaluation PACE New Jersey Study Generalized estimating equation model estimated difference prevalence ever past 30day use cannabis subtypes Waves 13 MarchNovember 2021 n  1439 Wave 4 JuneJuly 2022 n  1127 adultuse retail sale began Ever cannabis use among New Jersey young adult higher postretail sale period presales 581  vs 489  p  001 odds ever cannabis use 42  higher 95  CI  32 54  postretail period Ever use dried herb post vs pre 444  vs 385  p  001 drink 70  vs 48  p  001 edible 459  vs 356  p  001 topicals 64  vs 46  p  005 past 30day edible use 118  vs 90  p  001 higher postretail use product type differ Cannabis use overall among certain subtypes eg edibles increased among New Jersey young adult three month adultuse cannabis retail sale began demonstrating increased access legal cannabis sale may encourage use Continued monitoring needed longer followup period New Jersey state legalizing cannabis",
        "mesh_terms": [
            "Humans",
            "New Jersey",
            "Young Adult",
            "Male",
            "Female",
            "Cannabis",
            "Adolescent",
            "Commerce",
            "Marijuana Use",
            "Marijuana Smoking",
            "Prevalence",
            "Cohort Studies",
            "Legislation, Drug"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40618906/",
        "source_type": "Global"
    },
    {
        "pmid": "40616298",
        "title": "Qualitative research on the acceptance of evolving evidence for HTA body approval of innovative health technologies in selected European countries.",
        "abstract": "increasing effort streamlining market access innovative drugs current acceptance health technology assessment HTA body nontraditional trial design still unclear aim study assess perspective drug developer acceptance nontraditional trial design HTA body Europe Eleven semistructured interview conducted expert gain insight perception nontraditional trial design acceptance HTA body Netherlands Germany United Kingdom Sweden France Future perspective recommendation facilitating acceptance nontraditional trial provided expert highlighted HTA bodies preference randomized controlled trial nontraditional trial designs degree acceptance varied countries Experts recommended multistakeholder discussion drug developer HTA body early scientific advice reevaluation evidence requirements EUHTA regulation viewed potential opportunity harmonization limiting innovative approach result study highlighted significant variation acceptance nontraditional trial design HTA body across Europe Actions needed facilitate progressive view nontraditional clinical trial design ensure fast patient access highly innovative treatments",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40616298/",
        "source_type": "Global"
    },
    {
        "pmid": "40611094",
        "title": "Healthcare resource use and costs among patients with COVID-19 in the United States.",
        "abstract": "COVID19 remains common US uptodate data health care resource utilization cost remain limited particularly Omicron predominance study conducted using administrative claim data HealthVerity database available record medical claims pharmacy claims laboratory tests charge data master related enrollment including COVID19 events December 24 2021 April 30 2022 extracted Outpatient inpatient health care resource utilization HCRU cost 28day followup period COVID19 index date calculated total 1203769 patient COVID19 included HCRU analysis these 377945 nonmissing cost data included costing analysis median age 43 years 903  65 year age total 704 least one comorbidity 405 filled least one medication prescription potential major drugdrug interaction DDI ritonavir preceding 12 months Among COVID19 patients 444 outpatient 53 emergency room 12 urgent care visits 19 hospitalized Among hospitalized patients median length stay 3 days 189 admitted intensive care unit 34 required invasive mechanical ventilation Total mean treatment cost followup period 4965 outpatient 2686 pharmacy 2278 among patient never hospitalized 33329 among hospitalized patient with 22919 inpatient care HCRU treatment cost higher patient aged 65 older comorbidities medication prescription ritonavir DDIs regardless whether required hospitalization first four month Omicron wave economic burden COVID19 remained substantial Older age comorbidities associated higher HCRU treatment costs study provides data future research evaluating full economic impact COVID19 US",
        "mesh_terms": [
            "Humans",
            "COVID-19",
            "United States",
            "Female",
            "Male",
            "Middle Aged",
            "Adult",
            "Aged",
            "Health Resources",
            "Patient Acceptance of Health Care",
            "Health Care Costs",
            "Hospitalization",
            "SARS-CoV-2",
            "Comorbidity",
            "Young Adult",
            "Adolescent"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40611094/",
        "source_type": "Global"
    },
    {
        "pmid": "40610972",
        "title": "A survey of availability, price, and affordability of innovative negotiated anticancer medicines: a retrospective study in Jiangsu Province, eastern China.",
        "abstract": "emergence innovative anticancer medicine revitalized cancer treatment prospects improving accessibility innovative anticancer medicine key goal national pharmaceutical policies Despite significant effort National Medical Security Administration reform National Reimbursement Drug List NRDL concern regarding utilization newly included anticancer drug persist study aim assess accessibility 23 Innovative Negotiated Anticancer Medicines INAMs Jiangsu Province developed region eastern China retrospective survey conducted across 319 healthcare institution Jiangsu Province 285 included analysis Data obtained procurement record 23 INAMs evaluated use medicine based three aspects availability price measured defined daily dose cost DDDc affordability 435 23 INAMs encountered difficulty obtaining them 304 23 INAMs difficult obtain notable disparity availability 23 INAMs secondary tertiary healthcare institutions median DDDc Group Group C showed progressive annual reduction DDDc 19 INAMs decreased study period three drug remained unchanged one drugs DDDc actually increased Family poverty caused medicine pronounced among rural residents affordability rural patient significantly lower urban patient p  005 2021 2022 accessibility INAMs improved 2020 2022 However accessibility INAMs influenced various factors disparity still exist access across different healthcare institution urban rural areas Effective sustainable policy need developed ensure equitable access medicine patients",
        "mesh_terms": [
            "Retrospective Studies",
            "China",
            "Humans",
            "Antineoplastic Agents",
            "Health Services Accessibility",
            "Drug Costs",
            "Negotiating"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40610972/",
        "source_type": "Global"
    },
    {
        "pmid": "40609636",
        "title": "Referencing Drug Prices of Other Countries May Not Sustainably Lower Prices in the United States: Lessons From Europe.",
        "abstract": "Trump Administration issued Executive Order May 12 2025 intent equalize pricing across developed countries MostFavored Nation approach international reference pricing IRP IRP used extensively Europe resulted shortterm budget savings However list price quickly converged major highincome markets Germany France without evidence reduced prices Despite frequent use confidential price agreement differentiate net price country cannot afford price levels access innovative medicine delayed reduced suggests introduction IRP United States could limit access designated reference countries without sustainable reduction US price levels Instead referencing price countries United States establish system value assessment medicines whether time launch drug market several years",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40609636/",
        "source_type": "Global"
    },
    {
        "pmid": "40608336",
        "title": "Prescription Use and Spending After the Introduction of a Real-Time Prescription Benefit Tool.",
        "abstract": "Realtime prescription benefit RTPB tool provide pointofcare information clinician time prescribing may reduce prescription cost patient payers assess trend prescription use spending among Medicare Advantage beneficiary national health insurer first year clinician access RTPB tool cohort study used 2018 2020 administrative data national insurer compare prescription fill beneficiary receiving prescription clinician practice RTPB tool fill prescribed clinician without access tool Trends prescription spending fill year practice adopted RTPB tool in March 2019 measured using differenceindifferences design Data analyzed November 2022 June 2024 Access RTPB tool within national electronic health record software vendor main outcome total prescription spending beneficiary outofpocket spending number prescription fills Secondary outcome included percentage fill insurerowned mailorder pharmacy percentage fill 90day supply subgroup analysis drug class appearing frequently RTPB tool highcost prescription drug classes sample included 2 805 060 beneficiary mean SD age 709 92 years 567 female 147 Black individuals 805 White individuals mean SD monthly outofpocket cost 291 904 total prescription cost 2132 10663 26 21 prescription fill per month introduction RTPB tool change prescription spending estimated outofpocket spending change 12 95 CI 07 30 estimated total prescription spending change 05 95 CI 02 12 number prescription fill estimated change 001 95 CI 001 002 among beneficiary prescribed medication clinician practice RTPB tool cohort study 28 million patients simply providing clinician access RTPB tool associated anticipated benefit patient payer first year tool released research design deploy RTPB tool maximize potential benefit needed",
        "mesh_terms": [
            "Humans",
            "United States",
            "Female",
            "Male",
            "Aged",
            "Health Expenditures",
            "Medicare Part C",
            "Cohort Studies",
            "Drug Prescriptions",
            "Aged, 80 and over"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40608336/",
        "source_type": "Global"
    },
    {
        "pmid": "40608305",
        "title": "Health and Economic Impact of Periodic Hepatitis C Virus Testing Among People Who Inject Drugs.",
        "abstract": "Periodic hepatitis C virus HCV testing recommended people inject drug PWID optimal testing frequency remains unknown evaluate health benefits costs costeffectiveness alternative HCV testing frequency PWID costeffectiveness analysis extended previously published agentbased network simulation model HCV transmission sharing injection equipment among PWID Networkbased HCV transmission calibrated longitudinal data Social Networks Among Appalachian People study published literature PWID network US evaluate HCV testing strategy sparse PWID network setting lower HCV transmission dense network setting higher HCV transmission Data collected November 2008 August 2010 data analyzed September 2017 December 2019 Periodic HCV testing treatment alternative average testing frequency among PWID access use HCV care Changes cumulative qualityadjusted lifeyears QALYs health care cost 60 year in 2021 US dollars incremental costeffectiveness ratio ICERs discounted 3 annually mean initial age 1552 simulated PWID 32 years Compared testing HCV testing treatment among PWID 10year intervention period increased QALYs 25 46 cost 05 23 across average testing frequency ranging every 2 year monthly lower transmission setting testing every 2 year weakly dominated frequent testing strategies testing every year every 6 months every 3 months every month ICERs 6000 per QALY 9300 per QALY 24 200 per QALY 138 400 per QALY respectively higher transmission setting testing every 2 year every year weakly dominated testing every 6 months every 3 months every month ICERs 14 000 per QALY 30 100 per QALY 93 300 per QALY respectively Results sensitive risk primary infection reinfection well access utilization HCV testing service among PWID economic evaluation study based common benchmark costeffectiveness frequent HCV testing among PWID costeffective lower higher transmission settings",
        "mesh_terms": [
            "Humans",
            "Cost-Benefit Analysis",
            "Substance Abuse, Intravenous",
            "Hepatitis C",
            "Quality-Adjusted Life Years",
            "Male",
            "Mass Screening",
            "Female",
            "Adult",
            "Hepacivirus"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40608305/",
        "source_type": "Global"
    },
    {
        "pmid": "40607077",
        "title": "Biosimilars in dermatology: New opportunities and obstacles.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40607077/",
        "source_type": "Global"
    },
    {
        "pmid": "40606773",
        "title": "Program Report-Transplant Manitoba Adult Kidney Program Cutting Costs, Not Corners: Value of Quality Improvement Initiatives.",
        "abstract": "Provision highquality evidencebased patient care sustainable universal health system core Canadian Medical Education Directions Specialists CanMEDs expectation Transplant Manitoba Adult Kidney Program TMAKP embraced responsibility addressing inefficiency practice multipronged quality improvement QI strategies including reducing unnecessary interventions implementing innovative strategies aligning clinical practice emerging evidence Using seamlessly embedded continuous QI clinical research learning health system program achieved substantial cost saving increased opportunity deceased donor kidney transplantation purpose analysis measure cost saving associated QI initiatives Transplant Manitoba Adult Kidney Program database quality metrics Manitoba Health Physicians Manual April 1 2024 PubMed quantify potential cost savings employed 3pronged approach reduced testing costcounting exercise conducted using historical transplant activity 831 prevalent 83 incident patients project number test avoided direct cost per test Second cost saving generic mycophenolic acid presented ratio generic brand name drug costs projected cost saving prevalent patient receiving average dosing Third increased kidney utilization cost saving per kidney transplant derived published study extrapolated using predicted additional transplants Net health care system saving across payer assessed 1year time horizon TMAKP reduced unnecessary testing adopted generic medications implemented innovative strategies achieving 2530026 projected annual 1year cost savings QI initiative saving augment overall costeffectiveness kidney transplantation compared dialysis Implementing evidencebased protocol using personalized riskstratified approach viral monitoring novel donorspecific antibody surveillance strategy aligned testing clinical risk minimizing patient burden highlighting benefit seamlessly integrating research learning health systems Programs hepatitis Cviremic donor kidney agetargeted allocation increased transplant opportunity optimized deceased donor organ use Manitobas initiative demonstrate importance validation stakeholder engagement iterative adaptation driving sustainable improvement transplantation care Critically requires foresight health care administrative system invest effective ongoing QI embed research clinical practice improve patient health system outcomes analysis limited reliance projected cost savings require validation realworld audit confirm impact addition valuable QI efforts improving patient outcomes may increase costs highlighting need balanced perspective assessing stewardship initiatives Finally analysis limited projected cost saving evaluate clinical outcomes process adherence implementation effectiveness experience highlight potential QI initiative optimize care resource utilization within Canadas publicly funded health system effort reduced unnecessary testing minimized patient burden expanded transplant opportunities illustrating stewardship balance fiscal responsibility highquality stateoftheart patient care implementing evidencebased protocols TMAKP achieved additional 2530026 projected cost saving 1 year Future annual cost saving continue rising growing prevalent kidney transplant population Manitoba saving reallocated critical health care services expanding access improving outcome patient beyond transplantation",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40606773/",
        "source_type": "Global"
    },
    {
        "pmid": "40606225",
        "title": "Prescription for made in America? Tariffs and U.S. drug manufacturing.",
        "abstract": "Tariffs US pharmaceutical import recently proposed article examines potential effect tariff US domestic drug manufacturing focusing differential impact branded generic drugs contend generic manufacturing laborintensive operates thin profit margins strong competition usually constrains price increases However supply dominated tariffaffected country capacity limit may lead spotmarket price increases Unless tariffdriven global price increase outweigh amortized cost relocation higher domestic production costs US reliance foreign supplier generic likely continue contrast branded manufacturer greater incentive reshore production Branded manufacturers patentprotected monopoly provide sufficient pricing power absorb cost relocation Branded manufacturer also incentive relocate production active pharmaceutical ingredient APIs US Domesticallyproduced branded APIs could exported final processing lower cost imported back US finished drug without incurring tariffs Tariff policy uncertainty may influence manufacturers relocation decisions Among possible unintended consequence added pressure tariff global pharmaceutical manufacturers compromised product quality drug shortages higher prices retaliatory action like export quota bans reciprocal tariff stand out",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40606225/",
        "source_type": "Global"
    },
    {
        "pmid": "40604442",
        "title": "Global and regional burden of four drug use disorders in the elderly, 1990 to 2021: an analysis of the global burden of disease study.",
        "abstract": "global population ages burden drug use disorder DUDs among elderly rising imperative conduct quantitative analysis disease burden affecting vulnerable population Utilize Global Burden Disease Study 2021 database obtain incidence rate disabilityadjusted life year DALYs opioids cocaine amphetamines cannabis among elderly aged 6089 across 204 country 5 SDI region 1990 2021 Employ Joinpoint regression analysis calculate average annual percentage change AAPC agestandardized incidence rate ASIR agestandardized DALYs rate ASDR Use Das Gupta method decompose analyze impact change age structure population growth epidemiology DALYs period Finally apply Nordpred model predict DALYs global highburden region 2022 2035 four DUDs opioids highest disease burden Joinpoint analysis indicates 1990 2021 ASIR ASDR remained stable Cocaine use disorder ASIR remained stable ASDR increased AAPC 094 95 CI 077111 burden amphetamine cannabis use disorder generally stabilized Geographic heterogeneity evident regional national levels ASDR four DUDs increasing highSDI area remaining stable declining SDI areas Highincome North America represented United States show higher burden disease Decomposition analysis show population growth main factor affecting change burden DUDs regions highincome North America mainly affected epidemiological changes According Predictive models DALYs DUDs global elderly population still rise especially man group North America burden DUDs among elderly varies across countries regions SDI levels genders underscoring need targeted public health policy adjustment strategic allocation medical resource mitigate burden",
        "mesh_terms": [
            "Humans",
            "Aged",
            "Global Burden of Disease",
            "Aged, 80 and over",
            "Male",
            "Middle Aged",
            "Female",
            "Global Health",
            "Substance-Related Disorders",
            "Disability-Adjusted Life Years",
            "Incidence",
            "Cost of Illness",
            "Cocaine-Related Disorders"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40604442/",
        "source_type": "Global"
    },
    {
        "pmid": "40598486",
        "title": "Risk thresholds for soft versus hard cardiovascular disease outcome models for initiating statin therapy among Chinese adults: a cost-utility analysis.",
        "abstract": "Current guideline atherosclerotic cardiovascular disease ASCVD primary prevention mostly recommend risk score predict risk nonfatal myocardial infarction fatal ischemic heart disease IHD fatal nonfatal ischemic stroke hard outcomes ignoring burden nonfatal IHD outcomes explored optimal risk threshold statin initiation using nonlaboratorybased soft hard ASCVD outcome model compared costutility model Chinese population constructed Markov cohort model estimate incidence ASCVD events costs qualityadjusted life year QALYs lifetime social perspective simulation cohort constructed using data China Kadoorie Biobank CKB Input data included cost utility statin efficacy parameter derived published literature used CKBASCVD model predict 10year risk different risk threshold guide statin initiation incremental costeffectiveness ratio ICER estimated cost per QALY gained Sensitivity analysis performed explore uncertainty models optimal risk threshold 18 soft ASCVD model 10 hard ASCVD model ICERs 701348QALY 654071QALY respectively optimal threshold robust stratified analysis region sex oneway sensitivity analysis wide range input parameters Probabilistic sensitivity analysis showed optimal threshold around 70 chance costeffective analyzed age group optimal threshold costeffective adult aged 3059 year aged 6075 years threshold strategy based soft ASCVD model mostly costsaving compared based hard model treat proportion population risk threshold 18 soft ASCVD model 10 hard ASCVD model acceptable costutility profile Chinese population soft ASCVD model costeffective hard model used screening tool ASCVD primary prevention",
        "mesh_terms": [
            "Humans",
            "Cost-Benefit Analysis",
            "Hydroxymethylglutaryl-CoA Reductase Inhibitors",
            "Middle Aged",
            "Male",
            "Female",
            "China",
            "Quality-Adjusted Life Years",
            "Aged",
            "Markov Chains",
            "Cardiovascular Diseases",
            "Risk Assessment",
            "Adult",
            "Atherosclerosis",
            "East Asian People"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40598486/",
        "source_type": "Global"
    },
    {
        "pmid": "40598337",
        "title": "Analysis of the efficiency and effectiveness of technology transformation through the introduction of ADC in the Emergency Department: a Taiwanese case study.",
        "abstract": "study evaluates impact Automated Dispensing Cabinets ADCs workflow efficiency cost savings medication therapy management Emergency Department Taiwanese regional hospital ADCs key technology healthcare aimed improving efficiency effectiveness medication management processes Data collected hospital’s information system comparing one year one year ADC implementation study focused Emergency Department Dajia Hospital included comparison Shalu Hospital Additionally semistructured interview conducted nurse pharmacist gather qualitative insights implementation ADCs significantly improved workflow efficiency reducing time required drug preparation administration leading average time saving 2568 min per patient Cost saving realized 1099 reduction nursing activity costs amounting 8332625 annually ADCs also enhanced medication therapy management improving drug tracking availability However challenge manual error medication dispensing system limitation identified ADCs improve operational efficiency costeffectiveness Emergency Departments reducing healthcare professionals’ workload enhancing medication management Despite benefits ongoing training system optimization necessary address remaining challenge enhance overall performance online version contains supplementary material available 101186s12913025129816",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40598337/",
        "source_type": "Global"
    },
    {
        "pmid": "40594450",
        "title": "National and sub-national HIV/AIDS epidemiology, socioeconomic influences, and risk factors in Iran from 1990 to 2021, global burden of disease 2021 study.",
        "abstract": "Human immunodeficiency virus HIV remains global health challenge Iran face significant HIV issue rising incidence mortality rates antiretroviral therapy improved life expectancy projection indicate aboveaverage increase next years aimed report national subnational burden HIVAIDS risk factor Iran 1990 2021 sex age sociodemographic index SDI analysis used Global Burden Disease 2021 data agestandardized incidence rates prevalence death disabilityadjusted life year DALYs Cause Death Ensemble Model used estimate HIV mortality DisModMR 21 nonfatal outcomes Comparative risk assessment conducted evaluate burden HIVAIDS attributable risk factor condomless sex drug use intimate partner violence smoothing spline model used determine relationship SDI agestandardized DALY rate HIVAIDS count rate reported 95 uncertainty intervals 1990 agestandardized incidence rate HIVAIDS Iran among sex 02 01 07 prevalence rate 15 10 25 death rate 01 01 01 DALY rate 42 41 44 per 100000 2021 agestandardized proportion per 100000 follows incidence 23 18 30 prevalence 216 176 264 death 06 06 06 DALY 317 308 329 Males higher agestandardized rate female 2021 However female showed higher relative increase agestandardized rate 1990 2021 2021 3539 age group observed highest DALY rates Drug use leading risk factor 199 187 211 followed condomless sex 51 45 58 agestandardized DALY rate increased SDI SDI 065 decreased affected province Kermanshah Hormozgan Fars burden HIV Iran risen significantly male young adult affected Drug use leading risk factor infection following years interdisciplinary education policy healthcare effort necessary reduce burden incidence",
        "mesh_terms": [
            "Humans",
            "Iran",
            "Male",
            "Female",
            "Risk Factors",
            "Adult",
            "Global Burden of Disease",
            "HIV Infections",
            "Middle Aged",
            "Adolescent",
            "Incidence",
            "Young Adult",
            "Prevalence",
            "Socioeconomic Factors",
            "Acquired Immunodeficiency Syndrome",
            "Disability-Adjusted Life Years",
            "Child",
            "Aged"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40594450/",
        "source_type": "Global"
    },
    {
        "pmid": "40593655",
        "title": "Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa.",
        "abstract": "Although viral suppression attained adult living diagnosed HIV East Central Southern West Africa ECSWA challenge remain sustained adherence daily oral pill taking population Here evaluate potential effectiveness costeffectiveness introduction new combination longacting injectable drug lenacapavir  cabotegravir increase level sustained viral suppression find potential significant impact HIV death disability adjusted life years including due decrease mother child transmission lenacapavir  cabotegravir sourced cost around  80 per year less analysis suggests potential policy introduce costeffective setting ECSWA Recognising limitation modelling study suggest implementation study conducted confirm viability approaches",
        "mesh_terms": [
            "Humans",
            "Africa",
            "Anti-HIV Agents",
            "Cost-Benefit Analysis",
            "HIV Infections",
            "HIV-1",
            "Infectious Disease Transmission, Vertical",
            "Pyridones",
            "Acetamides",
            "Indazoles",
            "Diketopiperazines"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40593655/",
        "source_type": "Global"
    },
    {
        "pmid": "40588718",
        "title": "Beyond the jab: Modeling HIV vaccine acceptance in sexual and gender minorities with behavioral economic demand.",
        "abstract": "study investigation utility behavioral economic demand curve quantitative model showing consumption change price assessing acceptance hypothetical HIV vaccine among sexual gender minority SGMs Two experiment used simulated purchase task hypothetical scenario measuring purchasing decisions SGMs recruited Reddit LGBTQ community organization across United States Experiment 1 participant randomly assigned nine instructional set combining varying vaccine administration mode oral mucosal subcutaneous different dosage schedule one dose two doses one dose annually Experiment 2 examined bundling HIV vaccine one nine health commodity affected demand Participants also responded question assessing demographics HIV risk behaviors experience racial discrimination trust institutions result demonstrated exponentiated demand equation effectively modeled vaccine acceptance across condition median Rsup2sup  092 Contrary expectations vaccine characteristic minimal influence demand Q₀ Rsup2sup  0007 log α Rsup2sup  0001 Instead individual factor significantly influenced demand intensity consumption price  0 Q₀ price sensitivity sensitivity consumption increasing price α Significant predictor Q₀ included injection drug use history experience racial discrimination trust science Low household income strongest predictor log α Bundling HIV vaccine health commodity showed subtle effect acceptance condom dental examination significantly differing reference category finding suggest behavioral economic approach inform policy decision pricing bundling strategy targeted intervention maximize HIV vaccine uptake among SGMs face disproportionate HIV risk without requiring exposure nonmarketready vaccines",
        "mesh_terms": [
            "Humans",
            "AIDS Vaccines",
            "Male",
            "Female",
            "Adult",
            "Economics, Behavioral",
            "Sexual and Gender Minorities",
            "HIV Infections",
            "Young Adult",
            "Patient Acceptance of Health Care",
            "Adolescent",
            "Middle Aged"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40588718/",
        "source_type": "Global"
    },
    {
        "pmid": "40586741",
        "title": "Online Availability of Diamond Shruumz Before and After FDA Recall Initiation: Qualitative Assessment and Simulated Test Purchasing.",
        "abstract": "Reports hospitalization associated Diamond Shruumzbranded mushroomcontaining product October 2024 led manufacturers recall restricted sale distribution accessibility new emerging psychoactive product study seek assess continuing online availability mushroomcontaining edible product diverse ecommerce landscape specifically aiming identify characterize online availability recall initiation retrospective online market surveillance Diamond Shruumz product using structured automated search query employed identify online product marketing availability Online surveillance included monitoring multiple social medium platforms cannabis ecommerce websites search engine query June 22 June 27 2024 immediately preceding manufacturerinitiated recall Postrecall simulated purchase conducted July 12 2024 platforms website domain identified continuing actively market sell product online product listings Prior product recall total 4117 product listing across 1600 3886 social medium post usergenerated comments 11 027 cannabis ecommerce websites 2509 6094 hyperlink internet search query generated content analysis Review online source revealed 49 social medium posts 8 ecommerce shops 67 domain identified actively marketing selling product prior recall Postrecall identified 45 6716 remaining domain continued market product different online sources Simulated purchase revealed 15 3333 domain successfully transacted test purchase 30 6666 transaction failed account verification payment failure Diamond Shruumz recall exemplifies ongoing challenge unknown consumer harm associated new emerging substance marketed sold internet especially concerning product appeal younger audience variety edible flavored products recall initiated product became unavailable study found postrecall online vendor continued market sell products indicates ongoing challenge effectuate recall online enforcement diverse ecommerce landscape rapidly bring new novel psychoactive substance market",
        "mesh_terms": [
            "Retrospective Studies",
            "United States",
            "Internet",
            "United States Food and Drug Administration",
            "Humans",
            "Social Media"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40586741/",
        "source_type": "Global"
    },
    {
        "pmid": "40586645",
        "title": "Delay in receiving lab test results increases the costs of treating an episode of care for treating urinary tract infections.",
        "abstract": "provide first national study examining impact health care cost treating episode urinary tract infection function time delay receiving antimicrobial susceptibility test results used nationally representative data set privately insured adult dependents retrospective analysis included receiving urine bacteria test susceptibility testing ultimately diagnosed urinary tract infection Using regression analysis estimate episode carebased treatment cost associated day delay receiving susceptibility test result controlling patient age gender number comorbid conditions Delays receiving test result allow filling prescription diagnosis increase health plan treatment costs analysis looked patient susceptibility test ultimate diagnosis urinary tract infection examined day test two outcomes diagnosis prescription filled Even 1 day delay added 1600 2022 US dollars health plan spending treat condition additional cost traced increased hospitalization condition day delay Delays prescription filled added treatment costs Receiving test result day test could reduce treatment cost 40 whole range bacterial tests analysis focused one  urine bacterial susceptibility culture test  limited patient ultimately diagnosed urinary tract infection analysis provides first national estimate increased cost treating urinary tract infection due delay receiving test results Slow turnaround time receiving test result bacterial infection increase hospitalization health plan employer spending treating infections need new technology allow rapid result tests",
        "mesh_terms": [
            "Humans",
            "Urinary Tract Infections",
            "Male",
            "Female",
            "Retrospective Studies",
            "Middle Aged",
            "Adult",
            "Aged",
            "Anti-Bacterial Agents",
            "Episode of Care",
            "Microbial Sensitivity Tests",
            "Time Factors",
            "Young Adult",
            "Health Expenditures",
            "Adolescent",
            "United States"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40586645/",
        "source_type": "Global"
    },
    {
        "pmid": "40580411",
        "title": "A Cost-Effectiveness Analysis of Rivaroxaban Compared to Warfarin for the Management of Venous Thromboembolism in Western Kenya.",
        "abstract": "Access direct oral anticoagulant DOACs subSaharan Africa limited due prohibitive upfront costs making warfarin standard care many patients especially relying publicsector healthcare study evaluated costeffectiveness using DOAC rivaroxaban compared warfarin treating venous thromboembolism VTE cardiovascular disorder caused blood clot veins western Kenya developed discretetime individual statetransition Markov model simulate VTE patients qualityadjusted lifeyears QALYs annual treatment cost rivaroxaban warfarin therapy strategy Transition state probability derived realworld eventrate data observed patient treated rivaroxaban n  160 warfarin n  116 VTE Moi Teaching Referral Hospital western Kenya Basecase parameter value obtained cohort event rates local costs literaturederived utility values Costeffectiveness assessed 1year time horizon using incremental costeffectiveness ratio ICER threshold US602040 per QALY gained equivalent three time Kenyas 2021 per caput GDP Deterministic probabilistic sensitivity analysis conducted assess parameter model uncertainty 12 months total mean treatment cost per patient 21600 17300 using warfarin rivaroxaban respectively basecase analysis rivaroxaban therapy resulted additional 0023 QALYs per patient compared warfarin ICER  186200 per QALY gained Based probabilistic sensitivity analysis Monte Carlo simulation costs utility values event rate varied rivaroxaban costeffective compared warfarin 841 simulation willingnesstopay threshold 602040 per QALY Oneway sensitivity analysis scenario analysis stable rivaroxaban therapy resulting fewer cost higher QALYs study rivaroxaban clinically economically superior alternative warfarin research may catalyze discussion policymakers industry partner scale appropriate use rivaroxaban resourceconstrained settings",
        "mesh_terms": [
            "Rivaroxaban",
            "Humans",
            "Warfarin",
            "Cost-Benefit Analysis",
            "Kenya",
            "Venous Thromboembolism",
            "Anticoagulants",
            "Quality-Adjusted Life Years",
            "Markov Chains",
            "Female",
            "Male",
            "Factor Xa Inhibitors",
            "Middle Aged",
            "Cost-Effectiveness Analysis"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40580411/",
        "source_type": "Global"
    },
    {
        "pmid": "40578894",
        "title": "Process evaluation of a randomised trial of a triple low-dose combination pill strategy to improve hypertension control: a qualitative study.",
        "abstract": "High blood pressure BP significant global health issue many treated patient failing achieve BP control Triple Pill v Usual Care Management Patients MildtoModerate Hypertension TRIUMPH trial evaluated effectiveness costeffectiveness acceptability early use lowdose triple fixeddose combination BPlowering drug triple pill compared usual care management hypertension TRIUMPH trial showed superior BP control triple pill strategy compared usual care process evaluation TRIUMPH trial aimed explore contextual factor influenced trial outcomes implementation triple pill strategy mechanism effect potential barrier facilitator implementing triple pill strategy routine practice Guided UK Medical Research Councils framework semistructured interview conducted 23 patient 13 healthcare provider involved TRIUMPH trial Data analysed using framework analysis method NVivo Hypertension care Sri Lanka hindered absence systematic screening overcrowded public clinics Despite free medication provision public clinics long waiting time occasional stockouts posed challenges TRIUMPH trial intervention usual care delivered context better usual care including teambased management reduced waiting times monetary assistance travel routine adherence monitoring intensive followup triple pill strategy provided simplified regimen better access BPlowering medication better BPlowering efficacy Key barrier implementation routine practice included triple pills large size therapeutic inertia restrictive regulatory policy regarding fixeddose combinations Implementation triple pill strategy routine practice requires health system strengthening provider training supportive policy measure replicate effectiveness seen trial ACTRN12612001120864 SLCTR2015020",
        "mesh_terms": [
            "Humans",
            "Hypertension",
            "Antihypertensive Agents",
            "Female",
            "Male",
            "Qualitative Research",
            "Middle Aged",
            "Drug Combinations",
            "Sri Lanka",
            "Aged",
            "Cost-Benefit Analysis",
            "Drug Therapy, Combination",
            "Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40578894/",
        "source_type": "Global"
    },
    {
        "pmid": "40578822",
        "title": "International Price Comparisons for National Price-Negotiated Drugs in China: A Cross-Regional Analysis.",
        "abstract": "China long struggled high medical cost irrational drug pricing recently made significant progress implementing drug negotiation strategy effectively reduce price targeted drugs accurately depict drug price global scale crosssectional timeseries analysis conducted China using Multinational Integrated Data Analysis System data first quarter 2017 fourth quarter 2022 analysis compared price 140 pricenegotiated innovative drug across 15 country using five distinct price indicesAverage Price Index Laspeyres Paasche Fisher Chained Laspeyresaiming address gap understanding Chinas negotiated drug price globally five drug price index DPI showed general consistency revealed significant variation drug price across countries Chinas drug pricing reform successfully reduced drug cost alleviated financial burden patients offering insight developing countries Drug price index serve valuable tool monitoring price promoting transparency using PPPs may better reflect actual affordability provide reasonable assessment",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40578822/",
        "source_type": "Global"
    }
]